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ABSTRACT 
 
Myotonic dystrophy (DM) is a triple-repeat expansion, multi-systemic disease that 
affects one in eight thousand people worldwide. The cause of the disease is a 
progressive, abnormal expansion of CTG repeats (CUG
exp
) in the 3’-UTR of the 
DMPK gene (DM1) and CCTG repeats (CCUG
exp
) in the intron 1 of the ZNP9 
gene (DM2). The sequestration of muscleblind-like proteins (MBNL) by CUG
exp
 
or CCUG
exp
 causes splicing defects in more than 100 pre-mRNAs, resulting in 
various disease phenotypes. As such, therapeutic development for DM has mainly 
focused on agents targeting the CUG
exp
/CCUG
exp
 -MBNL1 interaction. This 
dissertation focuses on the development of rationally designed small molecules 
that target CUG
exp
 and CCUG
exp
, including their synthesis and studies of their 
biological activity.  
The background of DM with a focus on its molecular mechanism and various 
therapeutic approaches are reviewed in Chapter 1. Chapter 2 includes the story of 
how simple ligands targeting CUG
exp
 have been developed and investigations of 
the biological activity of acridine-based and bisamidinium-based ligands 
synthesized by others in our group. Chapter 3 focuses on the design, synthesis, and 
biological activity of bisamidinium-based ligands that target CCUG
exp
. 
Because other toxic pathways, including microRNA dysregulation in DM1 
heart tissue and the production of polypeptides via repeat-associated non-ATG 
translation, are induced by CUG
exp
, recent efforts on DM1 therapeutic approaches 
 iii 
have moved beyond just preventing the formation of CUG
exp
-MBNL1 complex 
and further focused on regulating the level of toxic CUG
exp
. Thus, Chapter 4 
discusses a multi-target approach for DM1 in which a ligand with a RNA-cleaving 
unit can bind both CTG
exp
 and CUG
exp
 and regulate the level of CUG
exp
.  
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 1 
Chapter 1 
Introduction to Myotonic Dystrophy 
1.1. Disease pathogenesis of Myotonic Dystrophy 
Myotonic dystrophy is a neuro-muscular, multisystem disease, affecting 1 in 8000 people 
worldwide.
1
 There are two types of myotonic dystrophy: myotonic dystrophy type 1 (DM1) and 
myotonic dystrophy type 2 (DM2).
1-2
 DM1 is caused by an expansion of CTG repeats from a 
normal level of 3550 to several thousands repeats in the 3’-untranslated region of the DMPK 
gene on chromosome 19q13.
2
 DM2 occurs when there is a 75- to 11000-CCTG repeat expansion 
in the first intron of the ZNF9 gene on chromosome 3q21 (Figure 1.1)
1
.
1-4
 The length of the 
expanded repeats is directly related to severity and onset of the disease.
5
  
                                                        
1
 The figure 1.1 was adapted from the following reference:  
Gatchel, J. R.; Zoghbi, H. Y. Nat. Rev. Genet. 2005, 6, 743–755. 
 
 
 
 
Figure 1.1. Mutated genes causing DM and early understanding in disease pathogenesis. The imbalance in 
MBNL and CELF family proteins results in missplicing of pre-mRNA directly correlating with disease 
phenotypes.  
 2 
It has been shown that the RNA transcripts from CTG and CCTG repeats are toxic and the 
causative agent of the disease. The RNA transcripts exert this effect by sequestering the 
muscleblind-like (MBNL) protein family, including the alternate splicing regulator MBNL1.
4
 
Additionally, there is an increase in the level of CUG-binding protein 1 (CUG-BP1), another 
splicing regulator; the process by which this happens is currently unknown. The decrease in 
MBNL1 levels and elevation of CUG-BP1 levels are hypothesized to lead to splicing defects of a 
large set of pre-mRNAs, which subsequently lead to DM symptoms of myotonia, muscle 
weakness, cataracts, hypertrophy, and insulin resistance (Figure 1.1).
5
  
 
 
Figure 1.2. DM1 pathogenesis. (CTG·CAG)n undergoes bi-directional transcription, generating (CUG)n and 
(CAG)n RNA. These two transcripts are translated to produce polypeptides that are potentially toxic. The CUG 
transcript sequesters MBNL proteins, preventing them from the normal functions and upregulates CELF1 (CUG-
BP1) protein. The change in levels of MBNL and CELF1 proteins results in splicing defects of more than 100 
pre-mRNAs, causing disease phenotypes at different levels. CUG repeats also interfere with iRNA and miRNA 
pathways. 
 3 
In addition, the CTG repeats were shown to undergo bi-directional transcription resulting in 
two transcripts, namely CUG and CAG repeats (CUG
exp
 and CAG
exp
). These transcripts are 
translated via repeat-associated non-ATG (RAN) translation to produce homopeptides, some of 
which were found to be toxic in other neurodegenerative diseases.
6
 Thus, Ranum and colleagues 
reported the existence of polypeptides in disease-relevant tissues of DM1 patients.
7-9
 Recently, 
Kalsotra and co-workers reported that the CUG repeat dysregulates the translation of Mef2 
protein, causing the microRNA dysregulation in DM1 heart tissues (Figure 1.2)
2
.
10,11
 Although 
the understanding of the molecular mechanism of the disease has expanded, there currently is no 
treatment for DM. The following sections will discuss DM1 therapeutic developments.  
1.2. Targeting DM1 at protein and DNA levels 
DM therapeutics have been developed based on the above understanding of the molecular 
                                                        
2 The figure 1.2 was adapted from the following reference: 
Pearson, C. E. PLoS Genet. 2011, 7, e1002018. 
 
 
Figure 1.3. Proposed repeat expansion mechanism occurred during DNA replication and repair.  
 4 
mechanism of the disease. Thus, supported by the discovery of disease foci, i.e., the MBNL1 
sequestration by CUG
exp
 and CCUG
exp
, and the function of MBNL1 protein in cells, an early 
potential therapeutic approach for DM was to increase the MBNL1 level in disease cells. For 
example, it was shown that overexpressing MBNL1 could suppress the CUG
exp
-induced toxicity 
in DM1 Drosophila and mouse models.
13-15
 Although the protein approach has a practical 
limitation, it supports the hypothesis that MBNL1 sequestration is an important event, thus 
encouraging scientists to pursue the CUG
exp
-targeting approach for disease treatment. 
Targeting the disease at the DNA level to induce a contraction of CTG·CAG or 
CCTG·CAGG repeats is considered the ultimate treatment for DM. Thus, a number of studies 
have been carried out to understand repeat expansion mechanism. Experiments using simple 
repeat expansion models in yeast, E. coli, mammalian cells, and mouse models have showed 
some consistency in the threshold of the repeat number required for the abnormal repeat 
expansion occurring in DM patients.
16-18
 Importantly, it was shown that the repeat expansion 
could happen during replication, DNA repair, DNA recombination, and transcription with the 
formation of (CTG)n and (CAG)n-loop regions as a key event.
12
 Whereas the replication factors 
(e.g. helicases, polymerases) could contribute significantly to repeat instability at the early stage 
of cells, repair proteins (e.g. MSH2 and MSH3) and the factors that are key components in the 
remaining processes are believed to play important roles in (CTG·CAG)n expansion at the later 
stage when replication is limited (Figure 1.3)
3
.
12
 Despite a significant effort to develop model 
systems, a precise understanding of how (CTG·CAG)n undergoes expansion is lacking, which 
limits the development of DNA-targeting therapeutics. In fact, several known anticancer agents 
                                                        
3 The figure 1.3 was adapted from the following reference: 
McMurray, C. T. Nat. Rev. Genet. 2010, 11, 786–799. 
  
 
 5 
were tested in DM patient cells showing random effects on (CTG·CAG)n instability including no 
change, repeat expansion, and contraction (Table 1.1)
4
.
18
 Although tested compounds possess 
off-target activities causing cellular toxicity, the study supports an approach of using small 
molecule to contraction of (CTG·CAG)n to its normal length. 
 
 
                                                        
4 The table 1.1 was adapted from the following reference: 
Gomes-Pereira, M.; Monckton, D. G. Mutat. Res. - Fund. Mol. M. 2006, 598, 15–34. 
Table 1.1. Effects of chemicals on repeat instability  
 
 6 
1.3. Targeting DM at the RNA level 
Development of DM therapeutics has been mainly focused on targeting CUG
exp 
or CCUG
exp
 to 
increase the level of MBNL1 in disease-model cells and animals. This focus is supported by the 
studies in which overexpression of MBNL1 in DM1 animal models could rescue several disease 
symptoms (discussed above). In addition, because CUG and CCUG repeats are located on non-
coding regions, targeting these repeats is believed to minimize unwanted effects. Thus, the 
structures of CUG and CCUG repeats and the binding mode of MBNL1 and the repeats were 
investigated. X-ray studies on simplified sequences containing CUG or CCUG repeats showed 
that the repeat adopts A-form duplex with UU or CU mismatches separated by GC base pairs, 
respectively.
20,21
 In addition, the CCUG transcript was hypothesized to have a slipped form that 
contains adjacent UU and CC mismatches.  
It was reported that MBNL1 has a preference for binding pyrimidine mismatches, but 
binding affinities, albeit somewhat lower, were also observed for other mismatches. The binding 
of MBNL1 to CUG
exp
 requires 2 UU mismatches and 4 GC base pairs with an involvement of 
four zinc fingers, sharing similarities with its pre-mRNA substrate cTNT.
22
 Thus, design of 
inhibitors of this interaction needs to consider the similarity of CUG
exp
 and the substrates 
carefully to minimize nonspecific binding. The MBNL1-(CUG)n binding was also studied using 
 
 
Figure 1.4. Interrupting MBNL1-CUG
exp
 interaction by small-molecule inhibitors. (a) CUG
exp
 forms a stable 
hairpin containing UU mismatches, which sequesters MBNL1 protein. (b) Inhibitors compete with MBNL1 to 
bind to CUG
exp
, displacing MBNL1. 
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single molecule techniques, showing that the MBNL1 binding stoichiometry is CUG
exp
-length 
dependent.
23
 Specifically, (CUG)4 is bound by one MBNL1 , whereas  three MBNL1 molecules 
bind (CUG)12 simultaneously.  Although the binding of MBNL1-CUG
exp
 has not been studied in 
cells or in vivo at a molecular level, the co-localization of MBNL1 and CUG
exp
 in DM1 patient 
cells and DM1 model cells  (i.e., HeLa transfected with a (CTG)n containing plasmid) provides 
strong evidence of the protein sequestration. Recent studies showed that the MBNL1-CUG
exp
 
interaction could be modified by other factors in cells.
24,25
  
CUG
exp
, the causative agent of DM1, has been targeted using antisense and non-antisense 
approaches. In particular, antisense oligonucleotides or small molecules that selectively bind to 
CUG
exp
 can inhibit its interaction with MBNL1 allowing the liberated MBNL1 to function 
normally (Figure 1.4). Several oligonucleotides were employed to disrupt the MBNL1-CUG
exp
 
interaction, and found to reverse the DM1 symptoms in Drosophila and mouse models.
8,26,27
 The 
modified versions of oligonucleotides not only inhibit the formation of MBNL1-CUG
exp
 
complexes but also regulate the level of toxic RNA via an RNase H-mediated mechanism.
27
 This 
approach is believed to terminate other toxic pathways caused by CUG
exp 
such as RAN 
translation and miRNA dysregulation. Although the antisense treatment requires an 
intramuscular injection or electroporation to increase the cellular uptake, an investment in the 
 
 
Figure 1.5. Peptide-based ligand developed by the Miller group. 
 8 
antisense approach by Ionis (formally ISIS) Pharmaceuticals has lead to phase II clinical trials as 
of early 2015.  
Whereas an effective method for the delivery of antisense agents may be still required for 
better efficacy, small molecules offer an alternative for DM1 treatment with their better cell 
permeability. Thus, we and other groups have focused on the development of small-molecule 
inhibitors based on multiple strategies including rational design, library screening, and 
combinatorial chemistry for past 8 years. This chapter covers the work on CUG
exp
-targeting 
small molecules reported by other groups; our work will be discussed in Chapter 2.  
In 2008, Miller and co-workers reported the use of resin-bound dynamic combinational 
chemistry to prepare the first examples of small molecule inhibitors of MBNL1-(CUG)n, which 
exhibited in vitro Ki values in the low micromolar range (Figure 1.5).
28
 Berglund and co-workers 
discovered that pentamidine and neomycin (Figure 1.6) could act as potential DM1 therapeutics 
and tested these compounds in the first cellular experiments in 2009. Pentamidine was tested 
further in a DM1 mouse model and showed partial rescue of splicing defects of Clc-1 and 
Serca1. However, the further application was limited by the high toxicity of this agent.
29
 A 
structure-activity relationship study was employed to develop pentamidine analogs with lower 
cytotoxicity and similar or even better bioactivities. Although none of pentamidine analogs 
 
 
 
Figure 1.6. Potential DM1 therapeutic ligands found by Berglund group. (a) Pentamdine. (b) Diamidines. (c) 
Actinomycin D. 
 9 
match the criteria, the Berglund group recently reported two diamidines (Figure 1.6b), known 
DNA group binders, as effective agents that were shown to fully rescue splicing defects of IR 
and cTNT pre-mRNA in a DM1 cell model. Interestingly, furamidine, one in two above 
diamidines, fully reversed Clcn1 pre-mRNA missplicing in a DM1 mouse model.
29
  
Very recently, actinomycin D (Figure 1.6c), an FDA-approved chemotherapeutic that binds 
to GC-rich DNA, was reported by the same group to suppress the level of toxic CUG repeats in 
the nanomolar concentration range.
30
 This finding supports the therapeutic approach of targeting 
the production of CUG repeats in disease cells, which is also focused in our group (see Chapter 
4). This approach not only prevents the formation of MBNL1-CUG
exp 
complexes but also 
eliminates other toxic pathways induced by CUG
exp
.  
 
 
Figure 1.7. Compounds developed by the Disney group. (a) Hoechst 33258 derivative containing an azido 
handle. (b) 6’-N-5-Hexynoate kanamycin A derivative containing an alkyne group. 
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Disney and co-workers have developed the other set of CUG
exp
-targeting compounds based 
on Hoechst and kanamycin A (Figure 1.7), known DNA and RNA binders, respectively.
32,33
 One 
of the most potent Hoechst-based compounds partially rescued the splicing defects of cTNT pre-
RNA in a DM1 cell culture and Clc-1 and Serca1 in a DM1 mouse model.
34
 Later, a series of 
assembled compounds containing multiple Hoechst molecules on a peptide scaffold showed a 
remarkable improvement in efficacy in DM1 model cells.
35
 Regarding aminoglycoside-based 
compound-development, they improved the potency and cellular uptake of kanamycin A-peptoid 
assemblies by conjugating them with D-Arg9, which can act as molecular transporter.
36
 To 
improve the potency of small molecules without a significant increase in molecular weight,  
Disney group developed a small molecule with a reactive group (Figure 1.8a)
5
, which can form a 
covalent complex with the target CUG
exp
. The covalent inhibitor with 2500-fold improvement in 
cellular activates was also used in a pull-down assay to determine its main targets in cells.
37
 
Because CUG
exp
 can cause other toxic pathways beside MBNL1 sequestration, Disney and co-
                                                        
5 The figure 1.8 was adapted from the following reference: 
Guan, L.; Disney, M. D. Angew. Chem. Int. Ed. 2013, 52, 10010–10013. 
 
 
 
Figure 1.8. Covalent molecules (a) and a scaffold containing photo-induced RNA cleaving group for 
conjugating with azido containing Hoechst 33258 (b). 
 11 
workers synthesized a bifunctional small molecule that targets CUG
exp
 and mediates photo-
induced RNA cleavage (Figure 1.8b).
38
 
The development of compounds targeting CCUG
exp
 for DM2 treatment has been 
transformed from DM1 targeting strategies because of similarities in the molecular mechanisms 
of DM1 and DM2. In 2009, a screening assay by the Disney group showed kanamycin A (Figure 
1.7b) possessed a binding affinity toward CCUG
exp
.
33
 By conjugating kanamycin A on a peptoid 
backbone, the resulting assemblies inhibited MBNL1-CCUG
exp
 at a nanomolar concentration. 
However, the huge increase in molecular weight and size of the compound could be problematic 
for water solubility and cellular uptake. Thus, they recently reported an approach of using 
CCUG
exp
 as a catalyst to assemble its own potent inhibitors in situ.
39
  
1.4. Conclusion 
Myotonic dystrophy is a model example of repeat diseases, having significant effects on human 
health quality and subsequent generation. Although discovered almost 100 years ago and 
undergoing an expansion in understanding of the disease pathogenesis within the past 20 years, 
there is still no cure for DM. Due to an urgent need of DM therapeutics, multiple groups 
worldwide have focused on different approaches to treat DM. One of the most promising 
candidates for DM1 therapeutics is an antisense oligonucleotide that is under a clinical phase II. 
Another alternative of using an antisense approach to overcome the limitation in cellular uptake 
and for developing an oral drug is using a small molecule approach. In this Chapter, 
development of small molecules or small molecule-based compounds by the Berglund and 
Disney groups was focused with the starting point from the hits found from library screenings. In 
Chapter 2, our work during past 8 years on rational design of small molecules based on X-ray 
structures of CUG
exp
 and CCUG
exp
 and their biological activities will be discussed. 
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Chapter 2 
Biological activities of CUG
exp
-targeting ligands
1
 
2.1. Introduction 
One approach for DM therapeutic development is to target the deleterious interactions of 
MBNL1 and CUG
exp
 or CCUG
exp
 using small molecules. To disrupt the MBNL1-CUG
exp
 
complex, small molecules can target either MBNL1 or toxic RNA transcripts in which 
CUG
exp
 and CCUG
exp
 were believed to be preferred targets because their locations in 
non-coding regions. A screening assay done by the Disney group revealed that small 
molecule binding to MBNL1 caused DM1 disease phenotype, which supports the strategy 
of targeting CUG
exp
.
1
 MBNL1-CUG
exp
/ CCUG
exp
 small-molecule inhibitors developed by 
other groups are based on hits from library screening and are discussed in Chapter 1. Our 
group is interested in developing small molecules that disrupt MBNL1-CUG
exp
/ CCUG
exp
 
using a rational design approach based on reported crystal structures of the toxic RNA 
transcript. In addition, we are attracted to this strategy because of a lack of small 
molecules with the capacity to target RNA with potency and selectivity. The A-form 
hairpin of CUG
exp
 containing repetitive UU mismatches separated by two GC base pairs
2-
4
 is distinct from other cellular single-strand RNA transcripts. Thus, finding agents to 
selectively bind CUG
exp
 could provide an important answer to the question of whether 
RNA is a druggable target. To design CUG
exp
-targeting small molecules, we have 
                                                        
1 Some of the material in this chapter was adapted from the following publications:  
Jahromi, A. H.; Nguyen, L.; Fu, Y.; Miller, K. A.; Baranger, A. M.; Zimmerman, S. C. ACS Chem. Biol. 
2013, 8, 1037–1043. 
Jahromi, A. H.; Fu, Y.; Miller, K. A.; Nguyen, L.; Luu M. L.; Baranger, A. M.; Zimmerman, S. C. J. Med. 
Chem. 2013, 56, 9471–9481. 
Wong, C.-H.; Nguyen, L.; Peh, J.; Luu, L. M.; Sanchez, J. S.; Richardson, S. L.; Tuccinardi, T.; Ho, T.; 
Chan, E. H. Y.; Chan, W.-Y.; Baranger, A. M.; Hergenrother, P. J.; Zimmerman, S. C. J. Am. Chem. Soc. 
2014, 136, 6355−6361.  
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conjugated a UU mismatch recognition unit and an RNA binding unit. This strategy is 
not only simple but has also provided several relatively potent and selective small 
molecules for targeting CUG
exp
, and the same general approach has been applied 
successfully to DM2. 
2.2. Development of intercalating ligands targeting CUG
exp
  
In 2009, our laboratory reported a simple molecule targeting CUG
exp
 that was rationally 
designed based on the reported X-ray structure of (CUG)12.
5
 Ligand 1 (Figure 2.1) was 
designed as a conjugate of a UU Janus-Wedge-recognition melamine motif and a known 
DNA and RNA-binding acridine unit that provides a hydrophobic driving force for 
binding. The triaminotriazine unit was proposed to form a base triplet with a UU 
mismatch or to induce a base flipping of a uracil while pairing the other uracil (Figure 
 
 
Figure 2.1. The first triaminotriazine-acridine conjugate designed by our group for targeting DM1 
N
HN
Cl
MeO
N
N
N
NHH2N
NH2
1
 
 
Figure 2.2. Proposed binding mode of a triaminotriazine unit and a UU mismatch. (a) Base triplet 
model. (b) Uracil flipping model. 
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2.2). This ligand was found to bind to d(CTG)2 and r(CUG)2 with low micromolar 
binding affinities (KD) as measured by isothermal titration calorimetry (ITC) and to 
inhibit MBNL1-(CUG)12 with an IC50 of 46 M determined using an electrophoresis 
mobility shift assays (EMSA).
5
  
However, cell-based experiments showed that 1 is not only poorly cell permeable 
but also highly toxic, possibly the result of non-specific intercalation of the acridine unit 
in the unstacked form with other DNA and RNA sequences. To improve the cell uptake, 
Dr. Haghighat Jahromi synthesized water-soluble derivative 2 (Figure 2.3) by 
conjugating a polyamine to 1.
6
 The presence of the polyamine tail can help 2 be easily 
transported through cellular membranes via the polyamine transporting system (PTS). 
The biological activity of 2 was studied in vitro, showing that in comparison to 1, ligand 
2 maintains the binding affinity and inhibition potency toward the CUG
exp
-MBNL1 
complex. In addition, the cytotoxicity of 2 was reduced in comparison to 1. 
To enhance the inhibition potency of ligands 1 and 2, Dr. Haghighat Jahromi 
developed dimeric ligands targeting CUG
exp
 by linking two core units of 1 by polyether 
or polyamine linkers. The length of linkers was varied to optimize the bivalent effect and 
find the best dimeric ligand. Of ten dimers prepared, 3 (Figure 2.4) was the most active in 
a surface plasmon resonance (SPR) assay with 206-fold stronger binding affinity and 
 
 
Figure 2.3. Ligand 2, a derivative of 1 with a polyamine tail for improving water solubility and cellular 
uptake 
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266-fold greater inhibition potency toward CUG
exp
 and CUG
exp
-MBNL1 complexes, 
respectively, in comparison with monomer 2.  
The in-cell biological activities of ligands 2 and 3, including their cytotoxicity and the 
ability of disrupting DM1 disease foci and rescuing the splicing defect will be described 
in Section 2.3. 
2.3. Cellular bioactivities of ligands 2 and 3 
2.3.1. Toxicity study of 2 and 3 using Sulforhodamine B colorimetric assay 
Sulforhodamine B colorimetric assays were performed to study how ligands affect cell 
viability.
7
 Sulforhodamine B, a bright-pink aminoxanthene dye, is known to bind to 
proteins. After treating with ligands, fixed cells were incubated with Sulforhodamine B. 
The amount of Sulforhodamine B bound to cellular proteins depends on the protein 
 
Figure 2.4. The most potent dimeric ligand. 
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Figure 2.5. Toxicity curve for ligand 2. Semi-logarithmic plot of percent HeLa cell death against log 
[2]. Error bars represent standard deviations from three independent experiments. Something about 
conditions should be said (pH, buffer and ionic strength, etc) or indicate that these can be found in some 
other section. 
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content of the cells, so this assay provides information about cell growth. HeLa cells were 
incubated with serial dilutions of 2. Cells that survived after 24-h incubation were stained 
with Sulforhodamine B. Fluorescence of bound Sulforhodamine B was measured and the 
percentage of cell death under ligand treatment was calculated from a comparison with 
untreated samples. Plotting the percentage of cell death against tested concentrations of 2 
provides a toxicity curve with an IC50 of 50 M, which is the concentration resulting in 
50% cell death (Figure 2.5). A similar experiment was performed with 3, showing less 
than 20% cell death at 75 M after 24-h incubation. However, longer incubations (36 h, 
48 h) showed that 3 was significantly more toxic than 2 with an IC50 of less than 10 M.  
2.3.2. Foci disruption by ligands 2 and 3 using fluorescence in situ hybridization  
The hallmark of DM1 disease is a sequestration of MBNL proteins by CUG repeats to 
form disease foci in the nuclei of DM1 cells. If the ligand binds to (CUG)n and inhibits 
the formation of the MBNL1-(CUG)n complex, the ribonuclear foci should disappear or 
not form in the first place allowing MBNL1 protein to disperse throughout the nucleus. 
To determine if ligands 2 and 3 are able to dissolve the DM1 foci, fluorescence in situ 
hybridization (FISH) experiments were performed. HeLa cells were co-transfected with 
DT960 plasmid containing truncated DMPK-(CTG)960 and GFP-MBNL1 plasmid co-
expressing GFP and MBNL1 proteins that are covalently linked to generate a DM1 
model cells. Thus, the fluorescence of GFP was utilized to locate MBNL1, while the 
FISH probe, 5’-Cy3-(CAG)10, was used to stain CUG
exp
. Transfected HeLa cells were 
treated with ligands 2 and 3, and spermine (N-[3-({3-[(3-aminopropyl)amino]propyl}-
amino)propyl] acetamide) as a negative control. The number of foci in each sample were 
counted, and then compared to untreated DT0 and DT960 controls.  
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(a) 
 
(b) 
 
 
Figure 2.6. Ligand 2 dissolves the disease foci in DM1 model cells in FISH experiments. (a) The 
disease foci present in DM1 model cells (row 2) as well as in a negative control sample (50 M) (row 
3). Ligand 2 disrupts the disease foci at two representative concentrations, 50 and 75 M after 48 h 
incubation (rows 4 and 5). Each box is (150x150) m. (b) Plot of the number of (CUG)n foci-containing 
cells versus different ligand concentrations by counting over 100 cells. The error bars are standard 
deviations of at least three independent experiments. 
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For cells transfected with CUG0 and GFP-MBNL1 plasmids, no Cy3 signal of FISH 
probe was observed because 5’-Cy3-(CAG)10 had no targets and was easily washed out in 
the washing steps resulting in much lower intensities compared to the signal observed for 
the CUG960 control. In addition, the GFP-MBNL1 signal was fully dispersed in the whole 
nucleus because there was no CUG960 to sequester GFP-MBNL1 (Figure 2.6 and Figure 
2.7). In contrast, GFP-MBNL1 sequestration by CUG
exp
 in the DM1 model cells was 
confirmed with a co-localization of Cy3-CAG10 (red signal) and GFP (green signal) as 
the yellow dots in nuclei (merged column, Figure 2.6 and Figure 2.7).  
Taking advantage of the inherent fluorescence of the acridine moiety, the ligands 
were observed to spread throughout the whole cell (Figure 2.6 and Figure 2.7), providing 
 
 
Figure 2.7. Foci dispersion in DM1 cells treated with dimeric ligand 3 (50 µM, 36 h incubation). To-
Pro 3, compound, GFP-MBNL1, and Cy3-CAG10 channels were observed by excitation at 633 nm, 405 
nm, 488 nm and 564 nm, respectively. 
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direct evidence of cell permeability. Approximately 75% of DM1 foci were dispersed for 
cells incubated with 2 for 48 h treatment (Figure 2.6b), whereas ligand 3 showed better 
cellular efficacy with 100% foci disruption after 36-h incubation (Figure 2.7). In contrast, 
no foci dispersion was observed for the cells treated with spermine control, supporting 
the important role of the recognition and binding units in the activity of ligands 2 and 3. 
2.3.3. Tracking GFP-MBNL1 foci dispersion by 2 and 3 using live cell imaging  
The promising results from the FISH study encouraged us to pursue live cell imaging 
experiments that utilized the fluorescence of acridine and GFP. Compared to the FISH 
experiment that provided information only after fixing the cells, live-cell imaging is able 
to look at single live cells and track their cellular events over time. Consequently, this 
approach can provide direct evidence of the GFP-MBNL1 dispersion from identified foci 
simply by monitoring the fluorescent signal of GFP.  
At the time ligands 2 and 3 were added, no signal was observed under the acridine 
channel, whereas bright green dots were observed using the GFP channel (488 nm) 
showing the sequestration of GFP-MBNL1 in the nucleus. After 2–7 h treatment, the 
acridine signal was obseved with excitation at 405 nm, which showed the cellular 
pernetration of the compounds, whereas the green signal of GFP-MBNL1 in puntate foci 
observed at t = 0 h gradually disappeared to be replaced by green GFP signal covering the 
whole nucleus. This observation provides direct evidence that the ligands penetrated both 
the cell and nuclear membranes and, outcompeted the GFP-MBNL1 for CUG
exp
 binding. 
This inhibition resulted in GFP-MBNL1 liberation and its spreading throughout the 
nuclei (Figure 2.8a and Figure 2.9).  
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Figure 2.8. Tracking GFP-MBNL1 dispersion under the treatment of 2. DM1 model cells treated with 2 
(75 M): (a) GFP-MBNL1 dispersion versus time. (b) A decrease of GFP fluorescence intensity by 
time. DM1 model cells without treatment of ligand: (c) No GFP-MBNL1 dispersion observed. (d) GFP 
fluorescence intensity was unchanged.  
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In constrast, in a control experiment without compound, dispersion of GFP signal 
was not observed over time and there was no signal observed when cells were excited at 
405 nm (Figure 2.8b). To quantify the change in GFP signal at the GFP-MBNL1 foci at 
least qualitatively, we plotted the change in fluorescence at representative foci. In ligand-
treated samples, there was a decrease in GFP fluorescence by time from 250 (t = 0 h) to 
50 (t = 7 h) fluorescence units (Figure 2.8c), wheras in untreated samples that signal 
remained mostly unchanged (Figure 2.8d). 
2.3.4. Reversal of IR pre-mRNA splicing defect in DM1 model cells by ligand 2 
The DM1 phenotype is related to splicing defects of a set of pre-mRNAs
8
 including 
insulin receptor (IR) resulting from a decrease in cellular levels of MBNL1.
8,9
 The IR  
 
 
Figure 2.9. Tracking GFP-MBNL1 dispersion under the treatment of 3: (a) GFP-MBNL1 dispersion 
versus time in DM1 model cells treated with 3 (50 M). (b) No GFP-MBNL1 dispersion observed in 
DM1 model cells without treatment of ligand. 
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splicing defect in DM1 is the dominance of the exon 11 skipped isoform A in comparison 
to the exon 11 included isoform B (Figure 2.10a). Because ligands 2 and 3 disrupted the 
interaction of MBNL1 and CUG
exp
 in DM1 model cells, we sought to perform splicing 
assays to examine if ligands can reverse the splicing defect of the IR minigene. Thus, 2 
 
Figure 2.10. Reversal of IR pre-mRNA splicing defects by ligand 2. (a) IR pre-mRNA missplicing in 
DM1. (b) IR splicing gel showing 2 rescued IR splicing defect at 50, 75, and 150 M. (c) Percent of 
isoform B in splicing experiments. Error bars represent standard deviations of at least three independent 
experiments. * P < 0.05; ** P < 0.005 (two tailed t-test). 
 
 26 
and 3 were treated with DM1 model cells as HeLa cells co-transfected with DT960 
plasmid and IR minigene-containing plasmid. 
Ligand 2 rescued about 40% of the splicing defects of the IR minigene pre-mRNA 
(Figure 2.10b and 2.10c), whereas no correction in IR splicing defects was observed for a 
spermine control. This result was consistent with confocal experiments in which 2 
disrupted MBNL1-CUG
exp
 foci but spermine did not. There was no statistically 
significant difference in IR splicing-defect correction with DM1 model cells treated with 
2 at different concentrations (50, 75 and 150 M), but 75 M was found as the best 
concentration taking into account both the IR splicing-defect rescue and the compound 
cytotoxicity (Figure 2.10b and c).  
In splicing experiments, ligand 3 was highly toxic after 20-24 h incubation with 
DM1 model cells with dots inside cells observed under normal microscopy, not allowing 
further splicing assays with 48 h incubation. Consequently, the protocol was edited to 
decrease the incubation time to 20–24 h, but the following step in the assay could not be 
performed because of the poor quality of the isolated total RNA. The RNA was 
considered as being in good condition with an A260/A280 of about 2.0 and was acceptable 
if that ratio was above 1.6, but the isolated RNA from cells treated with ligand 3 was 
around 1.2. Several samples of RT-PCR trials were performed with low-quality isolated 
RNA, but the bands on the splicing-experiment gel were faint and the results were 
inconsistent.  
2.4. Development of groove-binding ligands targeting CUG
exp
  
The main goal of the project is to develop a new set of CUG
exp
-targeting ligands with 
comparable CUG
exp
-binding affinity and MBNL1-CUG
exp
-inhibition potency and an 
 27 
improvement in cytotoxicity, water-solubility, and cellular uptake in comparison with the 
acridine-based ligands discussed above. Thus, Dr. Wong in our group designed another  
 
 
Figure 2.11. Structure of DB213 and the NMR structure of the compound on HIV-1 FS RNA reported 
by Butcher.
11
 The bisamidinium unit is highlighted in green. 
 
 
 
 
 
Figure 2.12. Design of bisamidinium-based ligands targeting CUG
exp
. (a) Overlaying structures of HIV 
fs RNA and CUG
exp 
(PDB: 3GM7). (b) DB213 covers seven base pairs on the HIV-1 FS RNA. (c) 
CUG
exp
-targeting bisamidinium-based ligands were designed by replacing dimethylammonium groups 
with triaminotriazine units. 
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CUG
exp
 binder based on a known RNA groove binder, DB213 (Figure 2.11).
10
 In 2011, 
Butcher and co-workers reported the NMR structure of DB213 on the major groove of 
HIV-1 frameshift site RNA (HIV fs RNA)
11
 that adopts a A-form hairpin structure. 
Overlaying the NMR structure of HIV fs RNA
11
 and the crystal structure of (CUG)6 
(PDB: 3GM7) shows many structural similarities (Figure 2.12a). Interestingly, DB213 
covers seven base pairs on HIV fs RNA that is exactly the distance between every third 
UU mismatch (Figure 2.12b). Thus, Dr. Wong designed a set of bisamidinium-based 
ligands in which the two dimethylamino groups of DB213 were replaced by 
triaminotriazine units for targeting UU mismatches. The aliphatic linker between the 
triaminotriazine and bisamidinium units was varied from three to five carbon atoms to 
optimize the activity of the ligand (Figure 2.12c). Isothermal titration calorimetry (ITC) 
studies done by Dr. Wong showed that ligand 5 exhibited the strongest binding affinity 
toward (CUG)12 with KD = 8 µM. To examine if substituent positions on the benzene ring 
would affect the binding affinity and activities of ligand, ligand 7 (Figure 2.13), a meta-
substituted analog of 5, was synthesized. Ligand 7 showed a similar binding affinity 
 
 
Figure 2.13. Ligands 7 and 8, a meta-substituted analog and an alkyne-containing derivative of 5, 
respectively. 
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toward (CUG)12 in comparison with 5. It is important to note that all bisaminidum-based 
ligands are water soluble, thus organic solvent (e.g. DMSO) was not required in most of 
biological assays. 
2.5. In-vitro biological activities of bisamidinium-based ligands 
The inhibition potency of bisamidinium-based ligands toward the CUG
exp
-MBNL1 
complex was determined using electrophoresis mobility shift assays (EMSA). The first 
EMSA experiment was to measure the binding affinity of CUG
exp
 and a truncated 
MBNL1. The 
32
P-labeled (CUG)12 was incubated with serial dilutions of MBNL1. The 
complexes and free RNA were separated on a PAGE gel (Figure 2.14a). Plotting the 
percentage of RNA bound against concentrations of MBNL1 gave a sigmoidal binding 
 
 
Figure 2.14. Binding study of MBNL1 and (CUG)12. (a) EMSA binding gel. (b) Binding curve of 
MBNL1 and CUG
exp
. Error bars represent standard deviations of three independent experiments. The 
detail of experiment can be found in section 2.8 (Materials and methods). 
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curve (Figure 2.14b) that was fitted to a standard binding equation providing an KD of 7 
nM.  
In the inhibition assays, each ligand serially diluted was incubated with MBNL1-
(CUG)12 complexes. Because of the very stringent conditions of the EMSA binding 
buffer (high salt buffer and the gel ran at 4 C), 25% DMSO was required to obtain the 
highest concentration of ligands. The RNA fraction bound was normalized to the control 
which contained 25% DMSO. The normalized RNA fraction bound was plotted versus 
the log function of ligand concentrations showing that 5 was the most active ligand in 
EMSA experiments with IC50 = 115 µM, which is consistent with ITC binding results 
(Figure 2.15). The corresponding Ki of ligand 5 is 2.6 µM, which is comparable to that 
measured for the acridine-based ligands. EMSA runs under different conditions using a 
higher percentage of Triton-X added to eliminate aggregates of the ligand showed a 
similar Ki = 3.6 µM (done by Dr. Richardson). In addition, inhibition assays were 
performed with several reported MBNL1-CUG
exp
 inhibitors (e.g. pentamidine,
12,13
 para-
H1, and meta-H
14
), showing much less potency in comparison with ligand 5. 
 
 
Figure 2.15. Inhibition study of ligand 5. (a) Inhibition gel. (b) Inhibition curve of ligand 5. Error bars 
represent standard deviations from three independent experiments. The detail of experiment can be 
found in section 2.8 (Materials and methods). 
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The other bisamidinium based ligands 4 and 6 had weaker inhibition potencies 
(Figure 2.16). The meta-bisamidinium-melamine 7 showed a comparably strong 
inhibition to MBNL1-(CUG)12 complex, but it is not as water soluble as 5. Additionally, 
alkyne derivative 8 synthesized by Long Luu (Figure 2.13) has a similar IC50 in 
comparison to 5 (Figure 2.16), suggesting the alkyne (or propargyl) substituents do not 
affect the inhibition potency of ligand. The preliminary data for 8 revealed an important 
ligand for use in Fragment Based Drug Design (FBDD), in situ click chemistry on the 
(CUG)n template, and a range of other strategies.  
2.6. Cellular biological activities of bisamidinium-based ligands 
2.6.1. Cytotoxicity study of ligands 4-8 using Sulforhodamine B colorimetric assay 
Because toxicity is an important factor that dictates testing concentrations and, more 
fundamentally whether a ligand can be further developed at all, SRB experiments were 
carried out with DB213, 4-8, and pentamidine following the protocol reported in the 
 
 
Figure 2.16. Inhibition study of bisamidinium-based ligands. IC50 values were obtained from three 
independent experiments, * from two independent experiments. 
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section 2.3.1. The bisamidinium-based ligands showed significant toxicity in comparison 
to acridine-based ligands with IC50 > 100 M for 3-d incubation (Figure 2.17). 
Additionally, toxicity studies were performed with mouse myoblasts and DM1 
fibroblasts, showing a similar result with no toxicity. Importantly, further cytotoxicity 
 
 
Figure 2.17. SRB toxicity profiles of (a) ligand 1 for 24 h, (b–e) DB213, ligands 4–6 for 72 h and (f) 
pentamidine for 24 h in HeLa cells. The detail of experiment can be found in section 2.8 (Materials and 
methods). 
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studies in mice revealed the MTD (maximum tolerated dose) of 5 in the range of 50 to 75 
mg/kg (performed by Dr. Rachel Botham, Hergenrother group). 
  
 
 
Figure 2.18. Foci dispersion by bisamidinium-based ligands (100 M, 48 h).  Very little detail here.  
Make sure you add the necessary detail or say explicitly that the detail is in the text or Experimental. 
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2.6.2. CUG
exp
-MBNL1 foci disruption by bisamidinium-based ligands 
The formation of MBNL1-CUG
exp
 foci is a key event in DM1. Thus, we performed 
FISH-immunofluorescence experiments to study if bisamidinium-based ligand can 
disrupt the interaction between MBNL1 and CUG
exp
 in DM1 model cells. HeLa cells 
were transfected with a DT960 or DT0 plasmid to generate DM1 model or normal cells, 
respectively. The CUG
exp
 was detected using a commercially available FISH probe, 5’-
Cy3-(CAG)10, whereas endogenous MBNL proteins were probed by anti-MBNL 
antibody followed with staining with an Alexa Fluro 488-containing secondary antibody.  
In untreated cells, punctate foci were clearly observed as a co-localization of CUG
exp
 
and MBNL proteins in DM1 model cells, whereas there was no CUG
exp
 detected and 
MBNL proteins spread throughout the nucleus in normal cells (Figure 2.18, rows 1 and 
2). DM1 model cells treated with 5, 7, and 8 at 100 M showed a significant reduction in 
the number and size of disease foci for 48-h incubation (Figure 2.18, rows 3-5). In 
 
Figure 2.19. Quantification of ribonuclear foci area in DT0 or DT960-transfected HeLa cells treated 
with ligands 5, 7, and 8 at 100 µM for 48 h. Error bars represent standard deviations from three 
independent experiments. * P < 0.05 (two tailed t-test). 
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particular, approximately 60% of foci dissipated (Figure 2.19). Further studies performed 
by Jessie Peh ( Hergenrother group) showed that 5 disrupted the disease foci in a time 
and dose-dependent manner.
15
  
2.6.3. Reversal of IR pre-mRNA splicing defects by ligand 5 
To examine if 5 was able to rescue splicing defects, splicing assays for IR and cTNT pre-
mRNAs were performed. For the IR splicing assay, HeLa cells were co-transfected with 
DT960 or DT0 and IR minigene plasmids were treated with 5 at 100 M for 24, 48, and 
72 h. The time-dependent experiments showed that 5 reversed IR pre-mRNA splicing 
defects after 72 h incubation, whereas the DB213 control did not (Figure 2.20a and b). 
More specifically, approximately 60% of splicing defect of IR pre-mRNA was corrected 
in comparison to untreated samples.  
 
 
Figure 2.20. Reversal of IR pre-mRNA splicing defect by ligand 5. (a) Gel of a time-dependent 
experiment. (b) Quantitative results of time-dependent experiments. (c) Gel of a dose-dependent 
experiment. (d) Quantitative results of dose-dependent experiments. Error bars represent standard errors 
of means from at least three independent experiments. * P < 0.05, ** P < 0.01, *** P  < 0.001 (two 
tailed t-test). 
 36 
The 72-h-incubation time point was selected for dose-dependent experiments in 
which DM1 model cells were treated with 5 at 20, 50, 75, and 100 M (Figure 2.20c and 
d). Treatment DM1 cells with different concentrations of 5 showed a rescue of the IR 
splicing defect at relatively low concentration (20 M), but no clear dose-dependence 
result was observed, possibly because splicing is a downstream event which is not 
directly related to the action of ligands or there might be other factors contributing to the 
IR splicing process. A similar result was obtained for cTNT splicing experiments 
(performed by Jessie Peh). 
2.7. Conclusion 
Our group has rationally designed small molecules targeting CUG
exp
 based on the crystal 
structure of the repeat RNA. These simple ligands contain one or two triaminotriazine 
units designed to target a UU mismatch covalently linked to a known RNA binding 
moiety (e.g., acridine or bisamidinium unit). Optimized acridine-based and 
bisamidinium-based ligands inhibited MBNL1-CUG
exp
 complexes in vitro, dispersed 
disease foci, and rescued IR pre-mRNA splicing defect in DM1 model cells. 
Bisamidinium-based ligands are much less toxic and more water-soluble, whereas the 
acridine-based ligands generally exhibit stronger binding affinity toward CUG
exp
. 
Interestingly, MBNL1-CUG
exp
 inhibition potencies of both sets of ligands were 
comparable, suggesting that a binding affinity and a physical barrier of ligands should be 
taken into account to determine how strongly a ligand can inhibit the MBNL1-CUG
exp
 
complex. Because of advantages in water solubility, cell uptake, and cytotoxicity, the 
bisamidinium-based ligand strategy was applied to DM2 and this will be discussed in 
detail in Chapter 3. 
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2.8. Materials and methods 
MBNL1 Expression and Purification 
An expression vector for a truncated MBNL1 comprised of amino acids 1–272 was 
obtained from Maurice S. Swanson (University of Florida, College of Medicine, 
Gainesville, FL). This MBNL1 construct is comprised of the four zinc finger motifs of 
MBNL1 and a hexahistidine tag (C-terminus) and binds RNA with similar affinity as the 
full length MBNL1. The protein was expressed and purified as described previously (7). 
The molecular weight was confirmed by MALDI-TOF mass spectrometry, the 
concentration was determined by Bradford protein assay (Bio-Rad), and the purity 
determined by silver-stained SDS-PAGE. 
 
Equilibrium Binding Assays  
(CUG)12 RNA was labeled with [-
32
P]-ATP using T4 poly-nucleotide kinase (New 
England Biolabs) and labeled RNA was purified by phenol extraction and ethanol 
precipitation. Labeled RNA and unlabeled RNA was heated at 95 °C for 5 min, then 
placed on ice for 10 min and diluted to protein binding buffer (175 mM NaCl, 5 mM 
MgCl2, 20 mM Tris-HCl (pH 8), 1.25 mM 2-mercapto-ethanol (BME), 12.5% glycerol, 
2mg/mL bovine serum albumin (BSA), 0.1 mg/mL heparin, 0.05% or 0.1% Triton X). 
For MBNL1-r(CUG)12 binding assay, MBNL1 was serially diluted in protein binding 
buffer and labeled and unlabeled RNAs were added to a final concentration of 0.22 nM 
(unlabeled RNA:labeled RNA = 10:1). The reaction mixture was incubated at room 
temperature for 20 min and loaded onto a 6% polyacrylamide gel (80:1) at 4 °C. The gel 
was run for 1.5 h at 150 V in Tris-borate buffer (pH 8). Gels were dried, developed 
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overnight in phosphor cassette and visualized on a Molecular Dynamics Storm 
PhosphorImager. The Kd (1:1 stoichiometry assumption) was obtained by fitting a plot of 
fraction RNA bound versus protein concentration (Prism) using the equation: Fraction 
RNA bound = Bmax×[MBNL1]total
h
/(Kd
h
 + [MBNL1]total
h
), where Bmax is maximum 
fraction RNA bound, h is Hill slope. The protein concentration in the reaction mixture 
was in a 10-fold excess over the RNA concentration. The average Kd and standard 
deviation were obtained from three independent experiments. 
 
Inhibition Assays  
Ligands 48 were dissolved in the protein binding buffer with 10% (v/v) DMSO at the 
highest concentration (3.4 mM) and the resulting stocks were serially diluted. 
Pentamidine was dissolved in water. Para- and meta-H1 were dissolved in DMSO. The 
inhibition assay was performed with the same procedure as in the Kd determination of the 
MBNL1-r(CUG)12 binding assay except the addition of small molecule to MBNL1-RNA 
complex. A mixture of RNAs, unlabeled and labeled RNAs with the ratio of 10, and 
MBNL1 was incubated at room temperature. After 15 min of incubation, the MBNL1-
RNA complex solution was added to the ligand solution to give final RNA and MBNL1 
concentrations of 0.22 nM and 0.1 M, respectively. The mixture was incubated 15 min 
and loaded onto a 6% polyacrylamide gel (80:1) at 4 °C. The gel was run for 1.5 h at 150 
V in Tris-borate buffer (pH 8). Gels were dried, developed overnight in phosphor cassette 
and visualized on a Molecular Dynamics Storm PhosphorImager. The fraction RNA 
bound versus log[compound] was fit (Prism) using the equation: y = ax
b
/(IC50
b
 + x
b
) 
where y =bound RNA fraction, x = ligand concentration, a = ymax – ymin, b = hill slope. 
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The average IC50 and standard deviation were obtained from three independent 
experiments. 
 
Plasmids 
Wild type cTNT, DT960 and DT0 minigenes were obtained from the lab of Thomas 
Cooper (Baylor College of Medicine). The insulin receptor (IR) minigene was obtained 
from the lab of Nicholas Webster (University of California, San Diego).  
 
FISH (Fluorescence In Situ Hybridization) 
A total of ca. 120,000 HeLa cells were seeded in each well of a 6-well plate on 
coverslips. After a day, the cells were transfected with 500 ng DMPK−CUG0 or 
DMPK−CUG960 plasmid and 500 ng GFP-MBNL1 plasmid using Lipofectamine 
following the manufacturer’s protocol at cell confluence of 70−80%. After 4 h, the media 
was changed and ligand was added to each well at desired concentrations. After 36 h or 
48 h, the cells were fixed with 4% PFA then washed five times with 1X PBS. Fixed cells 
were permeabilized with 0.5% triton X-100 in 1X PBS at room temperature for 5 min. 
Cells were prewashed with 30% formamide in 2X SSC for 10 min at room temperature. 
Cells were probed with FISH probe (1 ng μL-1 of Cy3 CAG10 in 30% formamide, 2X 
SSC, 2 μg mL-1 BSA, 66 μg mL-1 yeast tRNA) for 2 h at 37 °C. 
Cells were then washed with 30% formamide in 2X SSC for 30 min at 37 °C, 
followed by washing with 1X SSC for 30 min at room temperature. The cells were 
washed twice with 1X PBS and then nuclei were stained with 1 μM To-Pro-3 and washed 
twice. Cells were mounted onto glass sides with ProLong® Gold. Slides were imaged at 
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RT by LSM 710, AxioObserver confocal microscopy equipment using a confocal single 
photon technique with a plan-Apochromat 20x/0.8 M27 objective. Image analysis was 
performed by Axiovision interactive measurement. The following table indicates the 
excitation filters used in these experiments. 
 
Confocal Microscopy 
Approximate 120,000 HeLa cells were plated in each well of a 6-well plate onto 
coverslips maintained in complete growth media [DMEM (4.5g/L glucose) supplemented 
with L-glutamine and 10% FBS (Gemini)]. Cells were transfected at 70–80% confluence 
with 1 µg of DT960 plasmid with Lipofectamine 2000 (Invitrogen, Life Technologies) 
according to the manufacturer’s protocol. After 4 h, the transfection media was removed 
and the compound was added to the complete growth media if being assayed. For time 
course experiments, cells were treated with 100 M 5, 7, and 8 for 48 h.  
Cells were fixed for 10 min at room temperature with 4% PFA and washed 5 times 
for 10 min in 1X PBS at room temperature. Cells were stored at 4 °C if not probed 
immediately. For the fluorescence in situ hybridization (FISH) procedure, cells were 
permeabilized with 0.5% triton X-100 in 1X PBS at room temperature for 5 min. Cells 
were then prewashed with 30% formamide, 2X SSC for 10 min at room temperature. 
Cells were then probed for 2 h at 37 °C, with 1 ng/µL of Cy3-CAG10 probe (Integrated 
DNA Technologies) in 30% formamide (Fisher Scientific), 2X SSC, 20 µg/mL BSA, 66 
µg/mL yeast tRNA (Sigma-Aldrich). Cells were then washed for 30 min in 30% 
formamide, 2X SSC at 37 °C, and then with 1X SSC for 30 min at room temperature.  
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For immunofluorescent (IF) staining, cells were washed twice in 1X PBS, 10 min at 
room temperature, and then probed overnight at 4 °C with anti-MBNL1 antibody (1:5000 
dilution, clone 3A4 antibody, Millipore) in 1X PBS. Cells were washed 2 times for 10 
min at room temperature with 1X PBS. Next, cells were incubated with goat anti-mouse 
AlexaFluor 488 antibody (1:500 dilution, Invitrogen) for 2 h at room temperature. Cells 
were then washed 2 times for 10 min at room temperature with 1X PBS and then treated 
with 10 µg/mL Hoechst 33342 (Sigma-Aldrich) for 5 min. Finally, cells were washed 
with 1X PBS for 5 min and mounted onto glass slides with fluorescent mounting medium 
(Dako) before sealing with nail polish. Cells were imaged on Zeiss confocal laser 
scanning microscope (LSM) 700 at 20 or 40 magnification.  
 
Live cell imaging 
A total of ca. 120,000 HeLa cells were grown in an Ibidi 35 mm Petri dish with a 
standard bottom, high walls and an imprinted 500 Pm relocation grid. After a day, cell 
confluence reached to about 70−80%, cells were tranfected with 500 ng 
DMPK−CUG960 plasmid and 500 ng GFP-MBNL1 plasmid using Lipofectamine 
following standard protocol. After 4 h, media were changed and cells were incubated at 
37 °C, 5% CO2. 24 h post-transfection, ligand was added to a desired concentration. 
Live-cell, time-lapse images were taken before addition of 1 as well as at 2, 4 and 7 h 
time points at RT by a LSM 710, AxioObserver confocal microscopy equipment using a 
confocal single photon technique with a plan-Apochromat 20x/0.8 M27 objective. Image 
analysis was performed by Axiovision interactive measurement. For tracking the cells, 
DIC images were acquired simultaneously with the reflected light images using a TPMT 
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module after setting the Köhler illumination with a fully opened condenser aperture (0.55 
NA). 
 
Splicing assays 
Approximately 120,000 HeLa cells were seeded in each well of a 6-well plate in 
complete growth media the day before transfection. For testing the IR pre-mRNA, cells 
were similarly transfected the following day at 70–80% confluence with 500 ng each of 
IR and DT960 or DT0 minigenes with Lipofectamine 2000 (Invitrogen, Life 
Technologies) according to the manufacturer’s protocol. After 4 h, the transfection media 
was removed and ligand was added to the complete growth media if being assayed. Cells 
treated with 75 M of pentamidine were harvested 16–20 h post-treatment because of 
observed toxicity. For time course experiments, cells were treated with 100 M of ligand, 
harvested after 24, 48, or 72 h for 5 and after 72 h for DB213. Cells were treated with 3 at 
concentrations of 20, 50, 75 and 100 M, harvested after 72 h. To harvest the cells, cells 
were washed once with 1X PBS and detached using trypsin with 0.05% EDTA (Fisher 
Mediatech). Following harvesting, RNA was immediately isolated using Total RNA kit I 
(Omega Bio-Tek). 900 ng of isolated RNA was reverse transcribed with iScript cDNA 
synthesis kit (Bio-Rad) according the manufacturer’s protocol. The reverse transcription 
reaction was cleaned up using QIAquick PCR purification kit (Qiagen). Approximately 
70 ng of cDNA was subjected to 31–35 cycles of PCR amplification using gene specific 
primers. The forward primer was 5’-GTA CCA GCT TGA ATG CTG CTC CT, and the 
reverse primer was 5’-CTC GAG CGT GGG CAC GCT. The linear range for PCR for 
the IR constructs was found to be between 25–35 cycles. The PCR products were ran on 
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an 8% polyacrylamide gel with 1X TBE (National Diagnostics) at 120 V for 55 min. The 
gel was post stained with ethidium bromide and subsequently imaged using Gel Doc 
XR+ system (Bio-Rad). The bands were quantified using ImageJ (NIH).  
 
SRB Toxicity Assay 
The SRB assay was performed according to the method of Vichai and Kirtikara.
7
 DMEM 
supplemented with 10% FBS (98 L) was placed in a 96-well plate. Ligand solution (2 
L) was added to give final concentrations from 5 nM to 100 M, five repeats for each 
concentration. HeLa cells (10,000 cells/well), DM1 fibroblast cells (GM03132, ATCC) 
(10,000 cells/well), 3T3 cells (ATCC) (10,000 cells/well) were then plated in the 96-well 
plate. The cells were incubated at 37 C. After 72 h, 100 L of cold 10% (w/v) 
trichloroacetic acid were added in each well, followed by incubation at 4 C for 1 h. The 
cells were washed twice with tap water and then air-dried. The cells were stained with 
100 L of 0.0057% (w/v) sulforhodamine B in 1% acetic acid at room temperature, 30 
min. The plate was rinsed twice with 1% (v/v) acetic acid to remove the unbound stain. 
The bound protein stain was solubilized in 200 L of 10 mM Tris base, pH 10.5 and left 
for 30 min. The optical intensity was measured at 510 nm using microplate reader 
(SPECTRAmax PLUS). Percentage of dead cells was calculated using the following 
formula: 
% cell dead = 100%   
Mean D sample   Mean D dead control
Mean D live control   Mean D dead control
   100% 
The data was plotted using Excel and curves were fitted using Table Curve (Systat) to 
estimate the IC50 values. The cytotoxicity experiment was triplicated for HeLa cells. 
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Chapter 3 
Development of novel CCUGexp-MBNL1 inhibitors
1
 
3.1. Introduction 
Myotonic dystrophy type 2 (DM2) is associated with an expansion of CCTG repeats (CCTG
exp
) 
in the intron 1 of the ZNF9 gene on chromosome 3.
1
 In comparison with DM1, DM2 shows less 
severe symptoms with the estimated prevalence of 1 in 10000 people.
2
 The minimum length of 
the repeats indicating the presence DM2 diseases is 75 CCTG repeats. The sequence is unstable, 
progressively expanding and reaching thousands of CCTG repeats in the most severe cases of the 
disease. Transcribed CCTG repeats (CCUG
exp
) sequester muscleblind-like proteins including an 
important alternative-splicing regulator, MBNL1. A decrease in cellular MBNL1 levels results in 
splicing defects of >100 pre-mRNAs, leading to the disease symptoms, which include myotonia, 
muscle weakness, and cataracts.
2
 In addition, the CCUG transcript appears to interact with other 
proteins that are involved in translation.
2-4
 Thus, it was reported that the CUG binding protein 
(CELF1) and a translation initiation factor (eIF2) form a complex and both are sequestered by 
CCUG
exp
 as are the proteasome, both events leading to a reduction of the global rate of protein 
synthesis.
3-5
 The CCUG
exp
 transcript may affect the expression levels of the ZNF9 protein, and 
this may contribute to the DM2 phenotype, however the reports on this point are somewhat 
contradictory.
4-8
 An important potential approach to treating DM2 involves molecular 
intervention, the discovery and development of either oligonucleotides or small molecules that 
selectively disrupt the interaction of CCUG
exp 
with MBNL1 and other proteins. This same 
general approach has been applied to DM1 and is considerably more advanced.
9-19
 To our 
knowledge there are only two reports of small molecules that selectively target the toxic 
                                                        
1
 The material in this chapter was adapted from the following publication:  
Nguyen, L.; Lee, J.; Wong, C.-H.; Zimmerman, S. C. ChemMedChem 2014, 9, 2455-2462. 
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CCUG
exp
 transcript causing DM2 (Figure 3.1).
20,21
 In 2009, Disney and coworkers described a 
series of multivalent ligands displaying kanamycin A units with varying separations (see 1, n = 
1-3, m = 0-19), the best was the trimer which inhibited the (CCUG)47-MBNL1 interaction with 
nanomolar IC50 values in vitro.
20
  In 2011, and as described in more detail below, our group 
reported ligand 2 as a strong and selective inhibitor of the (CCUG)6-MBNL1 interaction. 
3.2. Design of groove binding DM2 ligands 
The design of novel small molecules targeting CCUGexp was based on the knowledge gained in 
recent work on ligands 2
21
 and 3
16
 that target DM1 and DM2 (Figure 3.2). Our group developed 
a simple ligand 2 for DM2 based on DM1-targeting ligand 3. Ligand 2 was composed of a 
triaminopyrimidine moiety recognizing CU mismatches in CCUG
exp
 hairpin and an acridine unit. 
The protonation of the pyrimidine due to its higher pKa leads to a Janus wedge moiety that was 
proposed to complement with the CU mismatch.
21
 The selectivity of ligands 2 and 3 was shown 
toward CUG
exp
 and CCUG
exp
, respectively, despite the structural similarities of the 
 
Figure 3.1. Two reported small molecules targeting DM2 
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triaminotriazine and triaminopyrimidine moieties. Thus, the triaminopyrimidine unit is key to 
our design of novel DM2 ligands.  
 
Ligands 2 and 3 contain an acridine intercalator that provides a hydrophobic driving force 
for binding. In addition, the stacking of the intercalating unit on the Janus wedge unit was 
expected, which showed a success in the suppression of the off-target binding of duplex DNA of 
ligand 3. However, ligands 2 and 3 exhibited poor water solubility, low cell uptake, and high 
toxicity. For example, treatment of HeLa cells with ligand 2 resulted in the death of more than 
90% of DM2 model cells after 48 h incubation (Figure 3.3). Bisamidinium compounds are 
known to possess excellent water solubility, high cellular uptake,
22
 and low cytotoxicity.
23
 In 
 
 
Figure 3.2. Design of bisamidinium-based ligands targeting DM2. (a) Acridine-based ligands for DM1. (b) 
Proposed binding modes of a triaminotriazine and a triaminopyrimidine to UU and CC mismatches, respectively. 
(c) Bisamidinium-based ligands targeting DM1 and DM2. 
 
 
Figure 3.3. Confocal image of cells treated with ligand 2. DM2 model cells as HeLa cells co-transfected with 
plasmids expressing (CCTG)1200 and GFP-MBNL1 were treated with 2 (50 µM, 48 h). CCUG
exp 
was stained by a 
FISH probe, Cy3-(CAGG)8. 
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addition, bisamidiniums with the appropriate substituents are taken up by the nucleus.
22
 Thus, 
ligand 4, a groove-binding bisamidinium ion, was selected to replace the acridine unit in the 
novel DM2 small molecules. In 2011, Butcher and co-workers reported the NMR structure of 
ligand 4 (DB213, R = NMe2) bound within the major groove of the HIV-1 frameshift RNA.
24
 
Importantly, Wong and coworkers
19
 noted that the HIV-1 stem-loop RNA adopts a remarkably 
similar A-form conformation to (CUG)12, and the distance between the ammonium ions in bound 
4 is the same as between every third UU mismatch in (CUG)12.   
As a conjugate of the bisamidinium groove binder 4 and two triaminotriazine recognizing 
UU mismatches, ligand 5 exhibited relatively low toxicity in HeLa, mouse myoblast, and DM1 
fibroblast, and was well tolerated by mice. Importantly, 5 was found to bind CUG
exp
, disrupt the 
disease foci, rescue cTNT and IR pre-mRNA splicing defects in DM1 model cells, and improve 
the eye phenotype in a DM1 Drosophila model.
19
 Whether CCUG
exp
 has a structural similarity to 
CUG
exp
 would determine if the similar approach could be applicable for DM2. It was predicted 
that CCUG
exp 
might adopt two possible structures: one with two consecutive CU mismatches or 
one referred as the slipped form with alternating CC and UU mismatches.
21,25
 After this work 
was completed, in 2014, Disney and co-workers reported the first high-resolution X-ray structure 
of an (CCUG)3 duplex within a larger RNA sequence.   showing that the CCUG sequence indeed 
adopts an A-form structure with two CU mismatches separated by two GC base pairs.
26
 
3.3. Synthesis of bisamidinium-based DM2 ligands 
With the considerations outlined above, analogous bisamidinium ligands for DM2 were 
synthesized by conjugating the bisamidinium groove binding unit and two triaminiopyrimidine 
Janus wedge units that target the CU mismatches in CCUG
exp
 (Figure 3.2).
21
 The substitution 
pattern of the bisamidinium unit may affect its cell permeability and localization, and its specific 
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fit to CCUG
exp
. Thus, ligands with para- and meta-substituted bisamidinium moieties were 
prepared, in which alkyl linkers vary from two to four methylene groups. This set of ligands was 
used to determine the optimum length and general fit in the groove.  
 
Ligands 6-11 were prepared from the appropriate meta- or para-bisimidate and the corresponding 
aminoalkylpyrimidine (Scheme 3.1 and Materials and Methods). The aminoalkylpyrimidine 
compounds were prepared using a modification of the procedure reported by Mascal and co-
workers.
27
 Briefly, the dicyanoalkyl phthalimide reacted with guanidine carbonate, followed by 
deprotection using hydrazine (Scheme 3.2 and Materials and Methods). 
 
 
 
Scheme 3.1. Synthesis of 6-11. Reagents and conditions: a) Et3N, EtOH, 25 °C, 24 h, 39-52% 
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Figure 3.4. Binding study of (CCUG)8 and MBNL1. (a) Structure of (CCUG)8. (b) Binding gel and (c) binding 
curve of (CCUG)8 and MBNL1. Error bars represent standard deviations from three independent experiments. 
For experimental details, see Materials and methods section at the end of this chapter. 
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3.4. Inhibition of MBNL1-(CCUG)8 complex by DM2 small molecules in vitro 
Electrophoretic mobility shift assay (EMSA) was performed to determine the inhibition potency 
of DM2 ligands toward MBNL1-(CCUG)8. The complementary GC-rich regions at the 3’- and 5- 
ends were used to avoid formation of the slipped CCUG
exp
 and restrict the structure to that with 
two consecutive CU mismatches (Figure 3.4a). The binding affinity of MBNL1N for (CCUG)8 
was determined using EMSA. Thus, radiolabeled (CCUG)8 was incubated with serially diluted 
MBNL1N, and the relative amount of free and complexed RNA were measured after a gel 
separation. The percent RNA bound by MBNL1N was plotted against the protein concentration, 
and curve fitting provided a KD value of 3.9 ± 0.8 nM (Figure 3.4b and c). 
The inhibition potency of DM2 ligands 2, 6-11 and DM1 ligands 5, 12-14 and the control 
compound 4 were qualitatively screened by incubating each at 100 µM with MBNL1N-(CCUG)8 
complexes. The relative ratios of free and MBNL1N-complexed (CCUG)8 were measured 
(Figure 3.5). 
 
 
Figure 3.5. Screening experiment. (a) Screening gel. In this gel, [(CCUG)8]= 0.22 nM, [MBNL1]= 33 nM, 
[ligand]=100 µM. (b) Graph of the percentage of RNA fraction bound versus ligands, showing 6, 8, 10, and 11 
were the potent ligands. Error bars represent standard deviations from three independent experiments (c) 
Structure of ligand included in the screening assay. For experimental details, see Materials and methods section 
at the end of this chapter. 
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Compounds 6, 8, 10, and 11 that contain linkers with three and four methylene groups fully 
disrupted the MBNL1N-(CCUG)8. In contrast, there was a significant amount of complex 
remained after incubation with the shorter ligands, 7 and 9, as well as for the negative control 4 
(DB213, R = NMe2) lacking triaminopyrimidine recognition units. Likewise, the DM1 targeting 
ligands containing triaminotriazine units failed to inhibit the MBNL1N-(CCUG)8 complex 
(Figure 3.5). Given the results of the screening assay, in collaboration with JuYeon Lee, we 
performed EMSA inhibition assays to determine IC50 values for ligands 6, 8, 10, and 11 (Figure 
 
 
Figure 3.6. EMSA inhibition experiment. (a) Inhibition gel of ligand 10. Briefly, MBNL1– (CCUG)8 complex 
was incubated with 10 at different concentrations (200 µM to 50 nM, twofold dilution). (b) The inhibition curve 
of ligand 10; the RNA fraction bound was normalized to the control. Error bars represent the standard deviation 
of at least three independent experiments. For more experimental details, see Materials and methods section at 
the end of this chapter. 
 
 
Table 3.1. Inhibition potency of DM2 ligands to MBNL1- (CCUG)8.  
 
Compound 
 
KD (nM)  
(MBNL1- (CCUG)8)  
Half-maximal inhibitory 
concentration 
IC50 (M) 
 
Inhibition constant 
Ki (M) 
6  
 
 
3.9  0.8 
73.4  6.0 8.7  1.9 
8 12.9  1.0 1.5  0.3 
10 14.7  1.2 1.7  0.4 
11 24.9  2.0 2.9  0.6 
 
 Data represent the mean  SD of three independent experiments performed in duplicate 
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3.6). The corresponding inhibition constants Ki were in the low micromolar range (Table 3.1). 
Interestingly, there is no significant difference in inhibition potency between meta- and para-
bisamidinium ligands. This result was unexpected because the substitution pattern changes both 
the distance that the recognition units can span as well as the fit of the bisamidinium unit within 
the RNA groove. Additional structural data is needed to explain the insensitivity to the 
benzamidinium substitution pattern.  
 
3.5. Low toxicity of DM2 ligands in HeLa cells 
Development of the acridine-based ligand 2 was limited by its high cytotoxicity. In particular, it 
was found that treatment of DM2 model cells as HeLa cells transfected with plasmids containing 
(CCTG)1200 with 2 at 50 µM led to more than 90% cell death, a change in cell morphology, and 
no significant reduction in the number disease foci after 48 h (Figure 3.3). In contrast, ligands 6, 
8, 10, and 11 showed a low cytotoxicity at 100 µM as incubated with DM2 model cells. 
 
 
Figure 3.7. Toxicity curves for ligands 6, 8, 10, and 11. The IC50 values for the toxicity, the concentration of 
ligand causing 50% cell death, was estimated from the plots. The error bars represent standard deviations from 
three independent experiments. For more experimental details, see Materials and methods section at the end of 
this chapter. 
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In collaboration with JuYeon Lee, cytotoxicity of bisamidinium-based DM2 ligands were 
quantitatively determined using a sulforhodamine B (SRB) colorimetric assay
28
 with HeLa cells. 
The percentage of cell death was plotted against ligand concentration (Figure 3.7), giving IC50 
values from curve fitting. Bisamidinium conjugates showed a low cytotoxicity with an IC50 of 
more than 100 µM for 3 d incubation, which is a significant improvement in comparison with 
ligand 2. In particular, para-bisamidinium based ligands 6 and 8 were observed to have low 
toxicity with between 15 and 30% cell death, whereas the meta-bisamidinium compounds 10 and 
11 exhibited essential no cytotoxicity under the testing conditions.  
3.6. Foci disruption in DM2 model cells by small molecules 
The hallmark of DM2 disease is the formation of foci resulting from the sequestration of MBNL 
proteins by CCUG
exp
. A co-localization of MBNL1 protein with CCUG
exp
 in DM2 patient cells 
was clearly observed as punctate foci in immunofluorescence experiments.
29
 With a similar 
pathogenesis to DM1, it is believed that the DM2 phenotypes might be reversed by small 
molecules able to disrupt the MBNL1-CCUG
exp
 complex in cells. As mentioned in the 
introduction there was a ligand reported by Disney to rescue the splicing defect, a downstream 
event, in DM2 model cells. However, no direct observation of small molecules dissolving 
disease foci in DM2 cell culture has been reported. Importantly, treatment of DM1 model cells 
with ligands targeting toxic CUG
exp
 repeats and interrupting the MBNL-CUG
exp
 interaction 
resulted in the reversal of the DM1 phenotypes.
9-19 
To examine whether the in vitro activity of 6, 8, 10, and 11 translated into cellular activity, 
fluorescence in situ hybridization (FISH) experiments were performed to study the ability to 
dissolve foci in DM2 of lead ligands 6, 8, 10, and 11. Thus, HeLa cells were co-transfected with 
GFP-MBNL1 and (CCTG)1200 plasmids to generate DM2 model cells.
3,4,26  
The locations of  
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Figure 3.8. Confocal microscopy images of foci dispersion. DM2 model cells were treated with compounds 4, 6, 
8, 10, 11 at 100 µm, 48 h; r(CCUG)n was probed by Cy3-(CAGG)8 ; the nucleus was stained by To-Pro 3. For 
experimental details, see Materials and methods section at the end of this chapter. 
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MBNL1 and the (CCUG)1200 transcripts were readily tracked by confocal microscopy, 
monitoring the fluorescent signal of GFP and Cy3-(CCAG)8 FISH probe, respectively (Figure 
3.8).  
The CCUG repeats were found to localize in both nuclei and cytoplasm, which is consistent 
with a report by Timchenko and coworkers.
4 
A co-localization of GFP-MBNL1 and (CCUG)1200 
within the disease foci was clearly observed, providing evidence of MBNL1 sequestration by 
CCUG repeats (row 2 in Figure 3.8). In addition, there were some (CCUG)1200 foci not co- 
 
localized with GFP-MBNL1, which might suggest a limited co-transfection of the protein or 
possibly the (CCUG)1200 transcript bound by endogenous MBNL or other protein complexes 
including the 20S catalytic core and the CELF1-eIF2 complex.
3,4
 
All of the bisamidinium ligands that inhibited the MBNL1-(CCUG)8 complex in vitro 
dissolved the disease foci with no co-localization of Cy3 and GFP signals (rows 4-7 in Figure 
3.8) whereas the control ligand 4 (DB213, R=NMe2) showed almost no foci dispersion (row 3 in 
 
Figure 3.9. Plotting percent normalized foci area per against different treatment conditions. DM2 model cells 
were treated with compounds 4, 6, 8, 10, 11 at 100 µm. Error bars represent the standard error of the mean of at 
least three independent experiments. *** indicates a statistically significant difference in comparison to 
untreated DM2 model cells, P < 0.001 (two tailed t-test). For more experimental details, see Materials and 
methods section at the end of this chapter. 
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Figure 3.8). Treatment of DM2 model cells with ligands 6, 8, 10, and 11 resulted in a significant 
decrease in the number and size of the foci. Thus, 50-70% foci disruption was observed after 48 
h treatment at 100 µM (Figure 3.9). There was no correlation between the Ki and the extent of 
foci disruption, which is understandable given that many other factors govern the cellular 
activity.  
3.7. Conclusion 
One therapeutic approach for myotonic dystrophy uses small molecules to target CUG or CCUG 
repeats and disrupt their interaction with MBNL1 and other proteins. In this chapter, a new set of 
ligands that inhibited the MBNL1-CCUG
exp
 interaction was reported. The ligands with low 
molecular weight of approximately 520 Da contain two important units: a triaminopyrimidine 
moiety for targeting the CU mismatch and a bisamidinium moiety. The bisamidinium unit 
provides a general A-form RNA targeting ability, confers excellent water solubility, and cellular 
and nuclear uptake. The linker length between the triaminopyrimidine recognition and the 
bisamidinium units and substitution pattern on the benzene ring were optimized. Four in six 
ligands show promising biological activity, inhibiting MBNL1-(CCUG)8 with low micromolar 
Ki values, very low cytotoxicity in HeLa cells, and dissolving the disease foci in DM2 model 
cells. Indeed, the low cytotoxicity of ligands 6, 8, 10, 11 and the binding selectivity of ligand 2 
toward a sequence containing CU mismatches
21
 suggest a specificity of bisamidinium ligands 
toward CCUG
exp
. With the promising results from in vitro inhibition experiments and cellular 
study, the bisamidinium-based DM2 ligands are appropriate for further testing to their ability of 
rescuing the disease phenotypes in DM2 Drosophila and mouse models.  
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3.8. Materials and methods 
Biological experiments 
Materials: r(CCUG)8 (5’-GCCCUGCCUGCCUGCCUGCCUGCCUGCCUGCCUGGC-3’) was 
purchased from Dharmacon RNAi Technologies (GE Healthcare) with 2’-deprotection, 
desalting, and HPLC purification. The r(CCUG)8 was dissolved in Ambion (Life Technologies) 
RNA storage solution (pH 6.4) to give a 1 mM stock solution. 
 
Protein expression and purification: An expression vector for a truncated MBNL1 contains 
amino acids 1–272. This MBNL is comprised of the four zinc-finger motifs of MBNL1and a 
His6, which has a similar affinity as the full-length MBNL1. The protein was expressed and 
purified following the procedure described previously.
29 
 
RNA radioactive labeling: (CCUG)8 was labeled with [ɣ-32P]-ATP using T4 polynucleotide 
kinase (New England Biolabs) and purified by phenol extraction and ethanol precipitation. 
Labeled RNA was heated at 95 ºC for 5 min, placed on ice for 10 min, and diluted in a binding 
buffer (175 mM NaCl, 5 mM MgCl2, 20 mM Tris (pH 7.5), 1.25 mM 2-mercaptoethanol, 12.5% 
glycerol (v/v), 2 mg mL
-1 
bovine serum albumin (BSA), 0.1 mg mL
-1 
heparin, 0.05% Triton- 
X (v/v)). 
 
Binding experiments: (CCUG)8 at a final concentration of 0.22 nm was incubated with MBNL1 
at serially diluted concentrations (3.3 μM to 2.1 pM). The reaction mixture was incubated at RT 
for 15 min, and loaded on 6% polyacrylamide gel (80:1) at 4 ºC. The gels were run for 2 h at 200 
V in 0.5M Tris borate buffer (pH 8.2). Gels were visualized on a Molecular Dynamics Storm 
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PhosphorImager. The apparent KD was obtained by fitting fraction RNA bound versus protein 
concentration using the equation: Fraction RNA bound = 1/(1+KD/[MBNL1]). The standard 
deviation was obtained from three independent experiments. 
 
Screening EMSA experiments: Each ligand at 100 μM was incubated with pre-incubated 
MBNL1–(CCUG)8 complexes at RT for 15 min. Final concentrations of MBNL1 and (CCUG)8 
were 33 nM and 0.22 nM, respectively. The reaction mixture was loaded on the gel as described 
above. Fraction RNA bound was compared to the control samples (H2O or DMSO) to determine 
the hits under the testing conditions. 
 
Inhibition EMSA experiments: Inhibition experiments were done as described above except 
MBNL1–(CCUG)8 complexes were incubated with ligands to give a serially diluted 
concentrations (from 200 μM to 50 nM). The IC50 values were obtained by fitting fraction RNA 
bound versus the log function of ligand concentrations using the equation: Y=B+(A-B)/(1+10
(X-
logIC50))
, in which Y = fraction RNA bound, B = minimum fraction RNA bound, A=maximum 
fraction RNA bound, X = log [ligand]. The inhibition constants (Ki) were obtained using the 
equation: Ki = IC50 x KD((CCUG)8-MBNL1)/ [MBNL1]. Standard deviations were obtained from three 
independent experiments. 
 
Cytotoxicity study: Toxicity of ligands in HeLa cells was studied following the protocol reported 
by Vichai and Kirtikara.
28
 Briefly, in a 96-well plate, HeLa cells were incubated at 37 ºC for 72 h 
with the treatment of the ligand. The ligand was added to each well to have serially diluted 
concentrations from 100 µM to 5.1 nM. The cells were fixed after 3 d and stained with 
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sulforhodamine B (SRB). Bound SRB was dissolved by Tris base solution (pH 10.5) and the OD 
was measured at 510 nm. IC50 values of toxicity were obtained by plotting the percentage of cell 
death against concentrations of ligands. 
 
Fluorescence in situ hybridization (FISH): FISH experiments were performed following the 
protocol described previously.
15
 Briefly, HeLa cells at 80% confluence were co-transfected with 
(CCTG)1200 and GFP-MBNL1 plasmids. Transfected HeLa cells were treated with ligands 4, 6, 
8, 10, and 11 at 100 µM, 48 h. rCCUG repeats were probed with Cy3-(CAGG)8, and the nuclei 
were stained with To- Pro 3. The cells were looked at under confocal microscope LSM 700 
(Zeiss). GFP, Cy3 and To-Pro 3 were excited at 488, 564, and 639 nm, respectively. Four 
random areas were selected to determine the average foci area per cell, using Teton software 
(version 4.7). The average foci area per cell of untreated cells was set to 100%. Each experiment 
was repeated at least three times independently. 
 
Synthesis of ligands tested in the study 
Triaminopyrimidine–bisamidinium conjugates were synthesized following Scheme S1 in the 
Supporting Information. 
1
H NMR spectra were recorded on a Varian Unity Inova 500 
spectrometer. All NMR measurements were carried out in [d6]-DMSO at RT unless otherwise 
stated. Chemical shifts are reported as parts per million (ppm). Mass spectra were obtained in the 
Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois, Urbana-
Champaign, USA. The analytical HPLC traces were obtained using a C18 column with 0.1% 
TFA in 1:1 (v/v) MeOH/H2O as eluent. All reactions were carried out under a nitrogen 
atmosphere. All solvents and reagents were purchased commercially with a reagent quality and 
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used without further purification. The progress of reaction was monitored by thin-layer 
chromatography (TLC) using Merck pre-coated silica gel 60F254. 
Ligand 2 was prepared using the procedure reported by Wong and co-workers, the 
characterization data was identical to that reported.[citation] The synthesis of intermediates can 
be found in the Supporting Information. HPLC traces of triaminopyrimidine–bisamidine 
conjugates show a purity of  ≥ 95% (see Supporting Information). 
 
N
1
,N
4
-Bis(4-(2,4,6-triaminopyrimidin-5-yl)butyl)terephthalimidamide hydrochloride salt (6): 
Et3 N (0.14 mL, 1.0 mmol) was added to diethyl terephthalimidate dihydrochloride (150 mg, 0.5 
mmol) in EtOH (10 mL) cooled in an ice bath. A solution of 5-(4-aminobutyl)- pyrimidine-2,4,6-
triamine (215 mg, 1.1 mmol) in EtOH (3 mL) and ethylene glycol (3 mL) was added dropwise. 
The mixture was warmed to RT and stirred for 24 h. The reaction was monitored by TLC using 
7:3 H2O/HOAc as eluent. The solvent was removed in vacuo. The residue was dissolved in 
MeOH and loaded onto a silica gel flash column and purified by chromatography 
(MeOH/CH2Cl2 = 1:4 to 4:1). The starting material and a side product were eluted, and the 
desired product was eluted with 4:1 MeOH/CH2Cl2 containing 0.04–0.08 mL of a 4M aq HCl 
solution in 1,4-dioxane per liter of solvent. The desired product fractions were combined, and the 
solvent was removed in vacuo to afford 6 as a light yellow solid, a hydrochloride salt (160 mg, 
48%): mp: > 230 ºC (decomp.); 
1
H NMR (500 MHz): δ = 10.36 (br s, NH2, 2H), 9.79 (br s, NH2, 
2H), 9.45 (br s, NH2, 2H), 7.99 (s, ArH, 4H), 7.15 (br s, NH2, 12H), 3.49 (br s, CH2, 4H), 2.33 
(br s, CH2, 4H), 1.75 (br s, CH2, 4H), 1.39 ppm (br s, CH2, 4H); MS (ESI): m/z (%): 521.1 (100) 
[M+H]
+
. 
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N
1
,N
4
-Bis(2-(2,4,6-triaminopyrimidin-5-yl)ethyl)terephthalimidamide hydrochloride salt (7): 
The desired compound was prepared using a procedure analogous to that described for 6 using 
diethyl terephthalimidate dihydrochloride (217 mg, 0.7 mmol) in EtOH (5 mL), Et3N (0.2 mL, 
1.4 mmol), and 5-(2-aminoethyl)pyrimidine-2,4,6-triamine (309 mg, 1.8 mmol) to afford of 7 as 
a light yellow solid (240 mg, 52 %): 
1
H NMR (500 MHz): δ = 10.37 (br s, NH2, 2 H), 9.75 (br s, 
NH2, 2 H), 9.64 (br s, NH2, 2 H), 8.04 (s, ArH, 4H), 6.85 (br s, NH2, 8H), 6.54 ((br s, NH2, 4H), 
3.49 (br t, J=2.5, CH2, 4H), 2.71 (br t, J=7.5, CH2, 4H); MS (ESI): m/z (%): 465.3 (100) [M+H]
+
. 
 
N
1
,N
4
-Bis(3-(2,4,6-triaminopyrimidin-5-yl)propyl)terephthalimidamide hydrochloride salt (8): 
The desired compound was prepared using a procedure analogous to that described for 6 using 
diethyl terephthalimidate dihydrochloride (150 mg, 0.5 mmol) in EtOH (10 mL), Et3N (0.14 mL, 
1.0 mmol), and 5-(3-aminopropyl)pyrimidine- 2,4,6-triamine (205 mg, 1.1 mmol) to afford 8 as a 
light yellow solid (150 mg, 47 %): 
1
H NMR (500 MH): δ =10.69 (br s, NH2, 2H), 10.30 (br s, 
NH2, 2H), 9.72 (br s, NH2, 2H), 7.93 (s, ArH, 4H), 7.25 (br s, NH2, 8H), 7.10 (br s, NH2, 4H), 
3.13 (br s, CH2, 4H), 1.61 (br s, CH2, 4H), 1.17 (br s, CH2, 4H). MS (ESI): m/z (%): 493.6 (100) 
[M+H]
+
. 
 
N
1
,N
3
-Bis(2-(2,4,6-triaminopyrimidin-5-yl)ethyl)isophthalimidamide hydrochloride salt (9): 
Et3N (0.25 mL, 1.8 mmol) was added to diethyl isophthalimidate dihydrochloride (255 mg, 0.87 
mmol) in EtOH (10 mL) cooled in an ice bath. A solution of 5-(2-aminoethyl)-pyrimidine-2,4,6-
triamine (309 mg, 2.4 mmol) in EtOH (2 mL) and ethylene glycol (2 mL) was added dropwise. 
The reaction mixture was warmed to RT and stirred for 24 h. The reaction was monitored by 
TLC using 7:3 H2O/HOAc as eluent. The solvent was removed in vacuo. The residue was 
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dissolved in MeOH and loaded onto a silica gel flask column and purified by chromatography 
(MeOH/CH2Cl2 = 1:4 to 4:1). The starting material and a side product were eluted and the 
desired product was eluted with 4:1 MeOH/CH2Cl2 containing 0.04–0.08 mL of a 4M aq HCl 
solution in 1,4-dioxane per liter of solvent. The desired product fractions were combined, and the 
solvent was removed in vacuo to afford 9 as a HCl salt as pale yellow solid (265 mg, 50 %): mp: 
> 230 ºC (decomp.); 
1
H NMR (500 MHz): δ =10.36 (br s, ArCNH, 2 H), 9.82 (br s, ArC=N+H2, 
2H), 9.63 (br s, ArC=N
+
H2, 2H), 8.47 (s, ArH, 1H), 8.13 (dd, J=7.8, 1.8, ArH, 2H), 7.81 (t, 
J=7.9, ArH, 1H), 7.01 (br s, CNH2C, 8 H), 6.77 (br s, NCNH2C, 4H), 3.48 (br t, J=7.4 Hz, 
NH2CH2, 4H), 2.74 (br t, J=7.6 Hz, CCH2CH2, 4H); MS (ESI): m/z (%): 465.3 (100) [M+H]+, 
233.1 (20) [M+H]
2+
. 
 
N
1
,N
3
-Bis(3-(2,4,6-triaminopyrimidin-5-yl)propyl)isophthalimidamide hydrochloride salt (10): 
The desired compound was synthesized following a procedure analogous to that described for 9 
using diethyl isophthalimidate dihydrochloride (150 mg, 0.5 mmol) in EtOH (10 mL), Et3N (0.14 
mL, 1.0 mmol) and 5-(3-aminopropyl)-pyrimidine-2,4,6-triamine (200 mg, 1.1 mmol) to afford 
10 as a pale yellow solid (120 mg, 39%): 
1
H NMR (500 MHz): δ =10.25 (br s, NH2, 2H), 9.78 
(br s, NH2, 2H), 9.49 (br s, NH2, 2H), 8.41 (s, ArH, 1H), 8.06 (dd, J=6.5, 1.5, ArH, 2H), 7.81 (dt, 
J=4, 1.5, ArH, 1H), 6.40 (br s, NH2, 8H), 6.01 (br s, NH2, 4H), 3.48 (br t, J=6.5, CH2, 4H), 2.38 
(br t, J=8.5, CH2, 4H), 1.67 (br q, J=3, CH2, 4H); MS (ESI): m/z (%): 493.6 (100) [M+H]
+
. 
 
N
1
,N
3
-Bis(4-(2,4,6-triaminopyrimidin-5-yl)butyl)isophthalimidamide hydrochloride salt (11): 
The desired compound was synthesized following a procedure analogous that described for 9 
using diethyl isophthalimidate dihydrochloride (150 mg, 0.5 mmol) in EtOH (10 mL), Et3N (0.14 
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mL, 1.0 mmol) and 5-(4-aminobutyl)pyrimidine-2,4,6-triamine (220 mg, 1.1 mmol) to obtain 11 
as a pale yellow solid (130 mg, 39%): 
1
H NMR (500 MHz): δ =10.35 (br s, NH2, 2H), 9.87 (br s, 
NH2, 2H), 9.47 (br s, NH2, 2H), 8.43 (s, ArH, 1H), 8.09 (dd, J=7, 1.5, ArH, 2H), 7.78 (t, J=7.5, 
ArH, 1H), 7.21 (br s, NH2, 12H), 3.49 (br s, CH2, 4H), 2.32 (br s, CH2, 4H), 1.78 (br s, CH2, 4H), 
1.42 (br s, CH2, 4H); MS (ESI): m/z (%): 521.1 (100) [M+H]
+
. 
 
 
Scheme 3.2. Synthesis of 6-11 
 
Phthalimide 16 (n = 1): The compound was synthesized by following the procedure reported by 
Mascal and coworkers.1 To a suspension of 435 mg NaH (10.9 mmol) (60% in mineral oil) in 5 
mL dry THF cooled in an ice bathwas added a solution of 1.2 g malononitrile (18 mmol) in 5 mL 
dry THF dropwise (malononitrile was recrystallized from diethyl ether). The reaction was 
allowed to proceed at room temperature for 30 min, and added dropwise to a suspension of N-
(bromopropyl)phthalimide in 10 mL dry THF. The reaction was refluxed for 12 h. The reaction 
mixture was poured into 50 mL water, extracted with DCM (3 Å~ 100 mL). The combined 
extract was dried over Na2SO4 to yield 2.51 g crude containing the desired product. The crude 
was used for next reaction without further purification. ESI-MS (m/z): 254.1 ([M+H]
+
, 100%. 
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Phthalimide 17 (n = 2): The compound was synthesized using the procedure analogous to that 
described for 16. NaH (578 mg, 14.5 mmol) in dry THF (10 mL), malononitrile (1.74 g, 26 
mmol) in dry THF (7 mL), N-(4- bromobutyl)phthalimide (3.71g, 13 mmol), 5.35 g crude was 
obtained. ESI-MS (m/z): 268.1 ([M+H]
+
, 100% Triaminopyrimidine-phthalimide 4 (n = 0): The 
compound was prepared using a modification of the preparation reported by Mascal and co-
workers.1 To a stirred solution of 2.5 g 2-(2-(1,3-dioxoisoindolin-2-yl)ethyl)malononitrile (10.5 
mmol) in 10 mL EtOH was added 1.1 g guanidine carbonate (12.2 mmol). The reaction mixture 
was heated to reflux for 12 h and cooled to room temperature. The solvent was removed in 
vacuo. The residue was filtered, washed with a cold EtOH, and dried in vacuo to afford 1.5 g 
(70%) of 3 as a pale yellow solid. This compound was used for following step without further 
purification. 
1H NMR (500 MHz): δ 7.86–7.79 (m, ArH, 4H), 5.42 (s, CCNH2, 4H), 5.20 (s, 
NCNH2C, 2H), 3.58 (t, J = 7.2, NCH2, 2H), 2.57 (t, J = 7.2, CCH2, 2H). ESI-MS (m/z): 299.1 
([M + H]
+
, 100%). ESI-HRMS (m/z): [M + H]
+
 calcd for C14H14N6O2, 299.1251, found 
299.1257. 
 
Triaminopyrimidine-phthalimide 18 (n = 0): The compound was prepared using a 
modification of the preparation reported by Mascal and co-workers.
1
 To a stirred solution of 2.5 
g 2-(2-(1,3-dioxoisoindolin-2-yl)ethyl)malononitrile (10.5 mmol)  in 10 mL EtOH was added 1.1 
g guanidine carbonate (12.2 mmol). The reaction mixture was heated to reflux for 12 h and 
cooled to room temperature. The solvent was removed in vacuo. The residue was filtered, 
washed with a cold EtOH, and dried in vacuo to afford 1.5 g (70%) of 3 as a pale yellow solid. 
This compound was used for following step without further purification. 
1
H NMR (500 MHz):  
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7.86–7.79 (m, ArH, 4H), 5.42 (s, CCNH2, 4H), 5.20 (s, NCNH2C, 2H), 3.58 (t, J = 7.2, NCH2, 
2H), 2.57 (t, J = 7.2, CCH2, 2H). ESI-MS (m/z): 299.1 ([M + H]
+
, 100%). ESI-HRMS (m/z): [M 
+ H]
+
 calcd for C14H14N6O2, 299.1251, found 299.1257. 
 
Triaminopyrimidine-phthalimide 19 (n = 1): The compound was synthesized using the 
procedure analogous to that described for 18. Crude containing 2 (2.51 g), guanidine carbonate 
(0.893 g, 4.9 mmol) in ethanol (20 mL). Obtain 1.3 g of 5 as a pale yellow solid. 
1
H NMR (500 
MHz): δ 7.88–7.84 (m, ArH, 4H), 5.50 (s, NH2, 4H), 5.01 (s, NH2, 2H), 3.62 (t, J = 7.0, 
NCH2CH2, 2H), 2.22 (t, J = 7.5, CCH2CH2, 2H), 1.60 (q, J = 7.5, NCH2CH2CH2, 2H). 
 
Triaminopyrimidine-phthalimide 20 (n = 2): The compound was synthesized using the 
procedure analogous to that described for 18. Crude containing 3 (5.35 g), guanidine carbonate 
(1.89 g, 10 mmol) in ethanol (30 mL). Obtain 1.22 g of compound 6 as a pale yellow solid. 
1
H 
NMR (DMSO-d6): δ (ppm) 7.87–7.82 (m, ArH, 4H), 5.38 (s, NH2, 4H), 5.08 (s, NH2, 2H), 3.57 
(t, J = 7, NCH2CH2, 2H), 2.15 (t, J = 8, CCH2CH2, 2H), 1.64 (q, J = 8, NCH2CH2CH2, 
2H), 1.27 (t, J =7, 4.5, NCH2CH2CH2, 2H). 
 
Triaminopyrimidine 21 (n = 0): The compound was prepared using a modification of the 
preparation reported by Mascal and co-workers.[1] To a stirred suspension of 1.5 g of 4 (5.0 
mmol) in 30 mL of EtOH was added 0.5 mL hydrazine hydrate (10.3 mmol). The reaction 
mixture was heated to reflux and the pale yellow solid was appeared. The reaction mixture was 
stirred for 12 h and cooled to room temperature. The solid was filtered, washed with 50 mL of 
water, and dried in vacuo to afford 0.70 g (83%) of compound 7 as a pale yellow solid. The 
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compound was used for next step without further purification. 
1
H NMR (500 MHz, DMSO-d6): 
δ 5.47 (s, CNH2C, 4H), 5.13 (s, NCNH2C, 2H), 2.47 (t, J = 7.6, NH2CH2, 2H), 2.24 (t, J = 7.3, 
CCH2CH2, 2H). ESI-MS (m/z): 169.1 ([M + H]+, 100%). ESI-HRMS (m/z): [M + H]+ calcd for 
C6H12N6, 169.1196, found 169.1203. 
 
Triaminopyrimidine 22 (n = 1): The compound was synthesized using the procedure analogous 
to that described for 21: 5 (1.3 g, 4.1 mmol), hydrazine hydrate (0.6 mL, 20.5 mmol) was 
refluxed in ethanol (40 mL) to obtain 800 mg of 8 as a pale yellow solid with small amount 
(approximate 20 % (mol/mol)) of 2,3-dihydrophthalazine-1,4-dione. 
1
H NMR (500 MHz): δ 5.52 
(s, NH2, 4H), 5.01 (s, NH2, 2H), 2.51 (t, J = 7.5, NCH2CH2, 2H), 2.20 (t, J = 7, CCH2CH2, 2H), 
1.60 (q, J = 7.5, 6.5, NCH2CH2CH2, 2H). 
 
Triaminopyrimidine 23 (n = 2): The compound was synthesized using the procedure analogous 
to that described for 21: 6 (1.2 g, 4.1 mmol), hydrazine hydrate (0.6 mL, 20.5 mmol) was 
refluxed in ethanol (40 mL) to obtain 635 mg of 9 as a pale yellow solid with small amount 
(approximate 15% (mol/mol)) of 2,3-dihydrophthalazine-1,4-dione. 
1
H NMR (500 MHz): δ 5.45 
(s, NH2, 2H), 5.15 (s, NH2, 2H), 2.57 (t, J = 6, NCH2, 2H), 2.16 (t, J = 7.5, CCH2, 2H), 1.42 (q, J 
= 7.5, 6, NCH2CH2, 2H), 1.30 (q, J = 7.5, 6.5, 6, NCH2CH2CH2, 2H). 
 
Diethyl terephthalimidate 24: The compound was synthesized followed the procedure reported 
by Wong and coworkers, the characterization data was identical to that reported.
19 
 
Diethyl isophthalimidate 25: To a stirred suspension of 2.9 g of 1,3-dicyanobenzene (22.6 
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mmol) in 35 mL absolute ethanol and 35 mL dry chloroform in ice was passed through by dry 
HCl gas for 5 h. The mixture was allowed warming up to room temperature and stirred for 24 h. 
The white solid was formed. The solid was filtered, washed with ether and dried in vacuo 
overnight, resulting 5.1 g (74%) of 11 as a white solid, a bisimidate esterhydrochloride. This 
ester was used directly in next step without further purification. 
1H NMR (400 MHz, CDCl3): δ 
9.96 (s, ArH, 1H), 9.58 (dd, J = 6.5, 1.5, ArH, 2H), 8.95 (t, J = 8, ArH, 1H), 5.74 (q, J = 7.5, 6, 
CH2, 4H), 2.56 (t, J = 6, CH3, 6). ESI-MS (m/z): 221.1 ([M + H]
+
, 100%). 
 
DM1 ligand 13: To 212 mg (0.72 mmol) of 10 in 8 mL EtOH cooled in an iced bath was added 
0.25 mL Et3N (1.8 mmol). A solution of 365 mg of N2-(4-aminobutyl)-1,3,5-triazine-2,4,6-
triamine (1.85 mmol) in 2 mL EtOH and 2 ml ethylene glycol was added dropwise. The reaction 
mixture was warmed up to room temperature and stirred for 24 h. The reaction was monitored by 
TLC with H2O-AcOH (v/v = 7:3) as eluent. The solvent was removed in vacuo. The residue was 
dissolved in methanol and loaded onto a silica gel flask column and purified by chromatography 
(MeOH-CH2Cl2 gradient from 3:7 to 7:3). Starting material and a side product were eluted and 
the designed product was eluted with 7:3 MeOH-CH2Cl2 containing 0.02–0.04 mL of a 4 M 
aqueous HCl solution in 1,4-dioxane per liter of solvent. The desired product fractions were 
collected and solvent was removed in vacuo to afford 233 mg (48%) of DM1 ligand 13 as a 
white solid, a hydrochloride salt, m.p. > 230 °C (decomp.). 1H NMR (500 MHz): δ 10.32 (br s, 
ArCHNH2, 2H), 9.89 (br s, ArCHNH2, 2H), 9.42 (br s, ArCHNH, 2H), 8.42 (s, ArH, 1H), 8.08 
(dd, J = 6.5, 1.5, ArH, 2H), 7.80 (t, J = 7.5, ArH, 1H), 6.70 (s, CNHCH2, 2H), 6.29 (s, CNH2, 
4H), 6.13 (s, CNH2, 4H), 3.48 (t, J = 6, NHCH2, 4H), 3.23 (q, J = 6.5, NHCH2, 4H), 1.71 (q, J = 
7.5, 6, 4, CH2CH2NH, 4H), 1.50 (q, J = 7.5, 6, 5, CH2CH2NH, 4H). 
13
C NMR (DMSO-d6): δ 
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166.6, 1662.2, 132.2, 129.7, 129.0, 43.1, 27.1, 25. ESI-MS (m/z): 523.3 ([M+H]
+
, 40%), 262.2 
([M+2H]
2+
, 70%), 175.1 ([M+3H]
3+,
 100%). ESI-HRMS (m/z): [M + H]
+
 calcd for C22H34N16, 
523.3225, found 523.3223. 
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Chapter 4 
Multi-targeting small molecules of Myotonic Dystrophy type 1
1
 
4.1. Introduction 
Drug discovery efforts traditionally place a high premium on agents that operate on a single 
target with high selectivity and affinity. However, rapid advances in “omics” have revealed the 
complexity of many diseases, especially cancer, where as many as 500 gene products may be 
dysregulated.
1
 In such cases, a “magic bullet” approach may be quite limited. Indeed, studies 
have suggested that in at least some cases less selective drugs exerting their pharmacologic effect 
on multiple targets can be superior to those with narrow activity profiles.
2
 These realizations 
have led some to suggest a paradigm shift from “single drug, single target” to polypharmacologic 
or multi-target drug discovery (MTDD) approaches.
2,3
 The main challenge in MTDD is the need 
to design a drug that modulates multiple disease targets simultaneously. Especially difficult is 
creating fused, hybrid structures whose different molecular segments recognize different targets. 
A much simpler strategy is to tether together two or more structural domains with different 
biological activities.
4,5
 These multiple ligands may be conjugates of two known inhibitors (e.g., 
of two signaling pathways) or a binding unit and a chemically reactive group.  
Although MTDD efforts have largely focused on protein targets, the increasing importance 
of RNA as a therapeutic target makes it an excellent candidate for MTDD. We were particularly 
attracted to myotonic dystrophy type 1 (DM1) because its complicated disease pathogenesis is 
increasingly well-understood, providing well-defined DNA, RNA, and protein targets for a 
small-molecule MTDD approach. DM1 is an incurable, multisystemic neuromuscular disease 
                                                        
1
 The material in this chapter was adapted from the following publication: 
Nguyen, L.; Luu, M. L.; Peng, S.; Serrano, F. J; Chan, W.-Y.; Zimmerman, S. C. J. Am. Chem. Soc. 2015, 137, 
14180-14189. 
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that is caused by an abnormal expansion of the CTG trinucleotide repeats (CTG
exp) in the 3′-
untranslated region of the DMPK gene on chromosome 19q13 (see Figure 4.1a, top box).
6
 This 
expanded DNA, which can reach 50−2000 CTG repeats, yields an expanded CUG RNA 
transcript (CUG
exp
) that sequesters the alternative-splicing regulator muscleblind-like protein 
(MBNL), leading to splicing defects and disease symptoms. We and others have developed small 
molecules that inhibit the MBNL1 sequestration by CUG
exp
.
7-14
 However, a recently expanded 
view of DM1 pathogenesis has suggested that additional CUG
exp
-induced toxic pathways must 
be considered for the disease phenotype to be fully reversed. In particular, the CTG·CAG repeats 
undergo bidirectional transcription, producing two transcripts, CUG
exp
 and CAG
exp
,
15,16
 that both 
undergo repeat-associated non-ATG (RAN) translation, generating multiple toxic 
homopeptides.
17,18
 Further, it was shown that CUG
exp
 disrupting the translation of the MEF2 
 
 
Figure 4.1. Schematic illustration of DM1 pathobiology and multi-target treatment. (a) RNA gain-of-function 
disease pathogenesis. The expanded DNA trinucleotide repeat (CTG
exp
) undergoes transcription to form a 
CUG
exp
 hairpin that sequesters MBNL proteins (e.g., MBNL1). The MBNL level depletion causes splicing 
defects of more than 100 pre-mRNAs, resulting in disease symptoms. RAN translation of CUG
exp
 and CAG
exp
 
generates toxic homopeptides. (b) Small-molecule intervention. Small molecules (green) target the CTG
exp 
hairpin, inhibiting production of CUG
exp
. Any CUG
exp
 formed is bound by small molecules, inhibiting MBNL 
and other protein sequestration. Cleaving functionality (red) processes the toxic RNA. All three small-molecule 
interventions free MBNL for its normal function. Likewise, other toxic pathways induced by the CUG
exp
 are 
eliminated. 
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protein, which affects multiple levels of mRNA and microRNA in human DM1 heart tissues.
19
 
Furthermore, the discovery of other proteins involved in the formation of MBNL1−CUGexp foci 
suggests that other toxic pathways may be induced by CUG
exp
.
20,21
  
The studies above suggest that a multi-target drug approach, especially one that degrades the 
toxic CUG
exp
 or inhibits its formation, may be more effective. Agents that perform one of these 
two functions are known. Thus, Cooper
22
 and Thornton
23
 reported antisense agents that induce 
CUG
exp
 cleavage via an RNase H-mediated mechanism and are currently in clinical trials, and 
Disney developed a small molecule that photodegrades the toxic transcript.
24
 Analogues of 
pentamidine were reported by Berglund to inhibit the synthesis of CUG
exp
 by binding to the 
(CTG·CAG)n duplex.
25
 We report herein a rational MTDD effort leading to small molecules that 
intervene in three separate steps in the DM1 pathobiology, suppressing CUG
exp 
mRNA levels 
and reversing the disease phenotype in DM1 model cells and a DM1 Drosophila model. 
Chart 4.1. 
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4.2. Design and synthesis of multi-target small molecules 
The overall approach was to develop agents able to intervene in the DM1 pathogenic mechanism 
in three ways: (1) targeting CTG
exp
 to inhibit the transcription to CUG
exp
, (2) targeting CUG
exp 
to 
inhibit the MBNL sequestration, and (3) hydrolytically degrading the CUG
exp
 with RNase-like 
catalytic functionality (Figure 4.1). Our group previously reported two classes of rationally 
designed agents (e.g. 1 and 2) that selectively bound CUG
exp
 and inhibited its interaction with 
MBNL with low micromolar Ki values.
11,12,26
 Both ligands feature triaminotriazine moieties to 
recognize the UU mismatch in duplex CUG
exp 
and provide sequence selectivity, whereas the 
acridine group in 1 and bisamidinium unit in 2 were selected to drive the association by A-form 
RNA intercalation and groove binding, respectively. Although 1 was not cell-permeable and 
poorly water-soluble, analogue 3 utilized the polyamine transport system to enter cells.
27,28
 The 
bisamidinium unit in 2 was chosen partly because it was reported to localize in cell nuclei. Both 
2 and 3 dissolved the MBNL−CUGexp nuclear foci and partially rescued splicing defects of IR 
and cTNT minigenes in DM1 model cell cultures (Chart 4.1).
12,27
 In comparison to 1, 
bisamidinium-containing 2 showed similar in vitro inhibition potency, but with lower toxicity, 
higher water solubility, and better cell uptake. Nonetheless, the acridine ligands are inherently 
multi-targeting because of their ability to bind both the DNA and RNA causing DM1. Thus, 
agent 1 complexes an oligonucleotide 10-mer containing a single dCTG and rCUG site with the 
binding constant KD = 0.39 and 0.43 nM, respectively.
11
 In contrast, agent 2 is selective for 
CUG
exp
, showing no detectable binding of dCTG by isothermal titration calorimetry (ITC) (vide 
infra). Beyond their ability to inhibit the sequestration of MBNL and other proteins, both 1 and 2 
have the potential to become CUG
exp
 cleaving agents with attachment of suitable functionality.  
Numerous small-molecule mimics of RNase A were developed over the past few decades.
29,30
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Many use the active-site functional groups found in RNase A in an effort to mimic its well-
established acid−base mechanism of action.31 Although none of the mimics cleaved RNA as 
effectively as RNase A, those containing at least one ammonium ion and an imidazole or amino 
group were the most promising. Based on this information, we designed agents 4−6, 8, and 9 
with side chains at the 2- or 4-position of the acridine ring (4−6) or attached to the 
triaminotriazine rings (8 and 9). 
The ability of these potentially catalytic functional groups to perform in the desired fashion 
was examined by modeling. Thus, the ligands were docked to binding sites prepared from the 
published X-ray analysis of (CUG)6 (PDB: 3GM7) using MOE (Figure 4.2), and each was found 
to reach at least one putative scissile phosphate bond. In collaboration with Long Luu, cleaving 
agents 4−6, 8, and 9 were synthesized following generally well-established procedures (Schemes 
 
Figure 4.2. Representative modeling of CUG
exp
 cleaving agent 6 with (CUG)6  using MOE. All synthesized 
CUG
exp
 cleaving agents were modeled on (CUG)6 (PDB: 3GM7) and (CUG)15 (for ligand 9) showing that the 
cleaving units can reach the phosphate backbone.  (a) Structure of ligand 6. (b) Minimized energy ligand 6 in 
water. (c) Modeling the binding of 6 on (CUG)6 . The bound conformer of ligand 6 was a local minimum with 
the potential energy of 131 kcal/mol.  Computational work is intended only to show that these flexible 
compounds are able to reach the backbone. 
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4.1−4.4, Materials and Methods). The synthesis broadly involved conjugation of di-Boc-
protected tris(2-aminoethyl)amine with the appropriate acridine acid chloride or chlorotriazine. 
The imidazole-bearing agent 6 was prepared from 5 by coupling one amino group with 
imidazole-4-acetic acid. The additional functional groups improved the water solubility, cell 
penetration, and affinity toward CUG
exp 
(Figure 4.3). 
 
4.3. DNA target activity: In vitro transcription inhibition of (CTG∙CAG)n by DM1 multi-
target small molecules 
As described above, simple ligand 1 binds CTG sites tightly, whereas 2 does not. Nonetheless, 
the additional ammonium groups in 9 might potentially increase its affinity for both CTG DNA 
and CUG RNA, so we examined its potential for inhibition of CTG
exp
 transcription along with 
that of ligands 5 and 6. The in vitro (CTG·CAG)74 transcription assays utilized a T7 promoter 
located in the upstream region of the repeats.
32
 Ligands 5 and 9 strongly inhibited the production 
of CUG
exp
 and in a dose dependent manner, whereas ligand 6 showed less inhibition (Figure  
 
 
Figure 4.3. Binding study of ligand 5 and (CUG)4 by reverse-titrations. (a) Change in fluorescence intensity of 5 
with increasing (CUG)4 concentration. (b) The plot of fluorescence change versus the concentration of (CUG)4 
in a range from 0-6 M provided an apparent dissociation constant KD of 86 nM as an average of two 
independent experiments. The sample was excited at 420 nm and the maximum emission was monitored at 490 
nm. Experiments were performed following a reported protocol.
1
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4.4). Control ligands 2, 7, and 10 had negligible effect on the transcription of (CTG·CAG)74 
 
Figure 4.4. In vitro transcription of (CTG·CAG)74. Ligands at different concentrations were incubated with 15 
ng of linearized plasmids in T7 RNA polymerase mixture at 37 °C. After 2 h, the reaction mixture was loaded 
on a 8% denaturing gel. (a) Transcription gels of ligands at different concentrations. (b) Plot of the percentage 
of transcription inhibition versus ligand concentrations. The error bars represent standard errors of mean of 
three independent experiments. 
(a) 
 
 
(b) 
 
 
 
Figure 4.5. In vitro transcription gels. (a) Control ligand 10 showed negligible effect on in vitro transcription of 
(CTGCAG)74. (b) Effects of ligands 6 and 9 on the transcription of control plasmids that contain no CTGCAG 
repeats. Ligand 6 showed negligible transcription inhibition whereas 9 strongly inhibited the formation of control 
plasmids at 100 and 50 M. However, the transcription inhibition of 9 is significantly reduced to less than 30% 
at 10 M. 
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(Figure 4.4 and Figure 4.5a). To test the selectivity and potentially the target of the inhibition, we 
performed similar experiments with two separate control plasmids each lacking repeats (see 
Materials and Methods for details). Ligand 6 showed negligible transcription inhibition at all 
tested concentrations, which ranged from 1 to 100 μM, whereas 9 strongly inhibited the  
 
transcription of the control plasmids at higher concentrations (i.e., 50 and 100 μM) (Figure 4.5b). 
However, 9 did show some selectivity with only 30% inhibition of the control plasmids observed 
at 10 M, whereas ca. 80% inhibition was obtained for the plasmid containing (CTG·CAG)74 
(Figure 4.4b). In collaboration with Julio Serrano, we determined the binding affinity of ligands 
2 and 9 toward the DM1 RNA and DNA. The lack of binding affinity shown by 2 toward 
Table 4.1. Equilibrium Dissociation Constants (apparent KD , μM) of Ligands 2 and 9 to Various Oligonucleotides 
Determined by ITC
a
 
Hairpin/Duplex 2 9 
(CUG)12 8 ± 2
b
 6 ± 4 
d(CTG)12 nb 5 ± 1 
d(CAG)12 nb nb 
d(CTG∙CAG)12 nb nb 
a
Apparent KD values were determined from at least three independent experiments; nb indicates no detectable 
binding. 
b
Data from Wong (ref 12). 
 
 
Figure 4.6. Cleavage screening gel. (CUG)16 (100 nM) was incubated with ligands (100 μM) in a Tris buffer 
(pH 7.4) containing 150 mM NaCl and 2 mM MgCl2, 18 h, 37 °C. HIV FS RNA (1 pmol) was used as an 
internal standard. The reaction mixture was loaded onto a 20% denaturing PAGE gel, and RNA was detected by 
poststaining with EtBr. Normalized % (CUG)16 intensity was reported as the average value of two independent 
experiments. 
 80 
d(CTG)12, d(CAG)12, and d(CTG·CAG)12 (Table 1), inhibits the transcription of CTG
exp
  by 
stabilizing its hairpin structure. Indeed, no strong binding was detected for d(CAG)12  or d(CTG· 
CAG)12. The in vitro transcription experiments using (CTG·CAG)74  and compounds 2 , 5−7 , 
and 9 were repeated but with (CUG)16 added as a competitor. In each case, the transcription 
inhibition of ligands was reduced, particularly for 6. 
4.4. RNA target activity: CUG cleavage by DM1 multi-target small molecules 
The potential cleavage activity of 4−9 was screened using a simple gel shift assay with (CUG)16. 
Thus, each agent at a final concentration of 100 μM was incubated for 18 h with unlabeled 
(CUG)16 at pH 7.4. The mixture was separated on an RNA denaturing gel and stained with EtBr 
(Figure 4.6). No loss of (CUG)16 intensity was observed upon treatment with 2, 7, or tris(2-
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. TAMRA−(CUG)16 cleavage gel, (CUG)16 and TAMRA structures . Ligand 9 or a control C as 
mixture of 2 (100 μM) and 10 (100 μM) was incubated with T-(CUG)16 (100 nM) in a Tris buffer (50 mM, pH 
7.4) supplemented with 150 mM NaCl and 2 mM MgCl2. OH is a control with RNA incubated in a buffer at 
pH 10.6. The reaction mixture was run on a 20% denaturing PAGE gel.  
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aminoethyl)amine (10), demonstrating that a polyamine or the CUG-targeting acridine or 
bisamidinium ligand on its own is insufficient to alter the (CUG)16. In contrast, a decrease in 
(CUG)16 intensity was observed for those ligands, i.e., 5, 6, 8, and 9, that contain a least one 
amino group, consistent with RNA cleavage (Figure 4.6). At least qualitatively, agents 6 and 9 
appeared to be most active. 
To observe potential cleavage fragments that were not observable in the screening gel 
because of the relative insensitivity of the EtBr post-staining, we performed similar experiments 
using 5′ -TAMRA-labeled (CUG)16 (T-(CUG)16). As seen in Figure 4.7, after 60 h of incubation, 
agent 9 shows a large number of bands. Interestingly, the intensity pattern corresponds to the 
repeat sequence, with every fourth band significantly more intense. This pattern may indicate a 
specific positioning of the catalytic groups by the ligand or possibly a higher reactivity of the UU 
mismatch site. Similar, although less distinct, patterns were seen at shorter (20 h) incubation 
times. RNA fragments were observed for a control incubation using a combination of ligand 2 
and tetraamine 10, but the reaction was much slower. Given the simplicity and ease of 
quantifying the loss of unlabeled (CUG)16 in the screening assay above, agent 9 was re-examined 
(b) 
 
Figure 4.8. Time- and dose-dependent cleavage experiments of ligand 9 using (CUG)16. (a) EtBr post-staining 
gels of time- and dose-dependent cleavage experiments. (b) Quantitative analysis of changes in (CUG)16 
intensity. The reaction mixture was loaded on a 20% denaturing PAGE gel. The percentage of (CUG)16 intensity 
was normalized to the control (no compound). Error bars represent standard errors of mean of three independent 
experiments. 
(a) 
 
 82 
at four different concentrations (5 − 100 μM). As seen in Figure 4.8, loss of the (CUG)16  band 
was both time- and dose-dependent. 
To better determine the origin of the loss of CUG
exp
 mRNA, the reaction of (CUG)4  with a 
3′ -TEG-biotin tag and 6  was monitored by MALDI. After a 5 h incubation with 6, fragment 
peaks were observed with lower m/z values, but no major change was seen in control samples  
(a) 
 
(b) 
 
Figure 4.9. (cont.) 
 83 
 
(Figure 4.9). The m/z values found matched the calculated m/z corresponding to hydrolysis 
products with 3′-hydroxyl end groups and selective cleavage in the loop and immediately 
adjacent to the loop. 
Cleavage experiments at different pH values and different concentrations of Mg
2+
 were 
carried out. The data from these experiments showed that the cleavage activity of ligand 9 was 
Mg
2+
 -independent and increased with increasing pH (Figure 4.10). The higher pH increases the 
concentration of the anticipated active species containing one amino group and one ammonium 
ion; however, the higher pH also increases the background hydroxide-catalyzed reaction. 
 
 
 
 (c) 
 
Figure 4.9. MALDI spectra of (CUG)4 cleavage of ligand 6. The cleavage sites corresponding to the most 
abundant peaks are indicated with red arrows. (a) RNA incubated with 6. (b) RNA incubated with control 
ligand 7. (c) RNA only. Biotin-labeled (CUG)4 (10 M) was incubated with ligands (100 M) or water in 
cleavage buffer (50 mM Tris buffer (pH 7.4), 150 mM NaCl, 2 mM MgCl2) for 5 h at 37 C. The reaction 
mixture was cleaned up using C18-Ziptip and subjected to MALDI.
2
 The fragments from MALDI-TOF 
were compared with the predicted values. The values of m/z with a mass-matching tolerance of 350 ppm 
were considered identical. 
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4.5. Selectivity of CUG
exp
 cleaving agents 
Off–target activity is a concern for any therapeutic agent but especially one designed to 
chemically alter its target (e.g., cleave RNA). To test the selectivity of agents 6 and 9, the 
cleaving gel assay described above was applied to other RNA targets, specifically cTNT32, 
(CCUG)8 , and HIV-1 frameshift site RNA (HIV FS) (Figure 4.11a). Both 6 and 9 were quite 
selective. Thus, neither agent showed detectable cleavage of cTNT32 or HIV FS, despite both of 
these RNAs having structures loosely analogous to CUG
exp
  (Figure 4.11). Both similarly adopt 
stem-loop structures with internal loops within the stem, although obviously of different 
sequence. Differences between 6 and 9 were observed with the former cleaving (CCUG)8, the 
toxic RNA involved in myotonic dystrophy type 2 (DM2) (Figure 4.11). In contrast, 9 showed no 
(a) 
 
 
 
 
 
(b) 
 
 
Figure 4.10. Factors affecting RNA cleavage activity of ligand 9. (CUG)16 cleavage study of 9 at difference 
concentrations of Mg
2+
(a) and pH (b). T-(CUG)16 was incubated with 9 (100 M) for 5 h in buffers containing 0, 
10, and 20 mM Mg
2+
 or at different pH values in a range from 6.7-10.6. The reaction was quenched by     8 M 
urea and the samples were loaded on a 20% denaturing PAGE gel. (-) no ligand added, (+) ligand with the 
concentration of 100 M added. 
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activity toward (CCUG)8. The ability to process the RNA directly parallels the corresponding 
ligand−RNA binding affinities. Thus, 1, which contains the acridine−triazine core of agent 6 , 
complexes (CCUG)6
33
 and (CUG)n  sequences (see also Figure 4.3). Likewise, 2 (the core of 
agent 9) complexes (CUG)n but showed no affinity toward (CCUG)8, cTNT32, or HIV FS.
12
 
These data are consistent with the catalytic functionality being brought into proximity of the 
RNA through selective binding. 
 
4.6. Bioactivity of multi-target agents in DM1 model cells 
The ability of 5, 6, and 9 to disrupt the MBNL1−CUGexp interaction in cells was evaluated using 
model DM1 cells. Thus, HeLa cells were transfected with GFP-DT0 or GFP-DT960 plasmids 
that contain 0 or 960 interrupted CTG repeats, respectively, in exon 15 of a truncated DMPK 
gene.
19,22
 The plasmids express both GFP protein and CUG
exp
 under the activation of 
doxycycline (Dox), with GFP being used as a marker for successful transfection and expression 
 
 
Figure 4.11. Selectivity study. (a) Structures of RNA oligonucleotides tested in the selectivity study. (b, c) Gels 
of potential cleavage of alternative RNA targets by ligands 6 and 9. RNA (100 nM) was incubated with ligands 
for 19 h at 37 °C. The reaction mixture was loaded on a 20% denaturing PAGE gel, followed by post-staining 
with EtBr. 
 86 
of the plasmids in the cells. Treatment of the DM1 model cells with ligands at 50 μM for 48 h 
was followed by analysis using confocal microscopy. As seen in the representative images in 
Figure 4.12, each of the three agents inhibited nuclear foci formation, leading to the dispersion of 
MBNL1 protein throughout the nucleus. 
 
 
 
Figure 4.12. Foci dispersion by agents 5, 6, and 9. DM1 model cells were incubated with 50 μM ligand for 48 
h. Cells were fixed, and CUG
exp
 was stained with Cy3-(CAG)10, and MBNL1 was probed with mouse anti-
MBNL followed by staining with goat anti-mouse Alexa 647 secondary antibody. The scale bar is 10 μm. 
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Because 9 is less toxic toward HeLa cells than 5 and 6, it was selected for a splicing study of 
insulin receptor (IR) minigene. Splicing of IR minigene is misregulated with the abnormal 
exclusion of exon 11 because of the MBNL1 depletion in DM1 cells.
34
 DM1 model cells, in this 
case HeLa cells co-transfected with plasmids containing IR minigene and (CTG)960, were treated 
with 9  at 100 μM for 3 days, leading to a 77% rescue of the IR  splicing defect (Figure 4.13). 
Encouraged by the promising results from the in vitro cleavage and the ability of 5, 6, and 9 to 
                                             (a)                                   (b) 
 
 
Figure 4.14. CUGexp mRNA levels in DM1 model cells. (a) Effects of ligands 5, 6, and 9 on CUGexp mRNA 
levels at 50 μM for 3 day treatment. (b) Ligand 9 reduced CUGexp mRNA levels in a dose-dependent fashion. 
Error bars represent the standard error of mean of at least three independent experiments; *P < 0.01, **P < 
0.005 (two tailed t-test). 
 
 
Figure 4.13. Ligand 9 rescued splicing defect of IR minigene. (a) Mis-splicing of IR minigene in DM1 model 
cells. (b) Percentage of exon 11 inclusion in HeLa (healthy model cell). DT960 (HeLa co-transfected with IR 
plasmid and DT960 plasmid expressing (CUG)960), and DT960 cells treated with 9 for 3 d. The splicing 
experiments were performed following a reported protocol.
3
 Error bars represent the standard error of mean from 
at least three independent experiments. * P < 0.05, ** P < 0.005 (two tailed t-test). 
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enter cells and dissolve MBNL1− CUG nuclear foci, we performed experiments to study whether 
the agents could control the level of toxic CUG
exp
 in cells using a reported protocol.
19,22
 Two sets 
of cells, transfected with either GFP-DT0 or GFP-DT960 plasmids, were incubated with 5, 6, or 
9  for 3 d. The CUG
exp
 mRNA level was determined by measuring the level of exon 15 upstream 
of the CUG
exp
 relative to PABP mRNA as a control, followed by normalizing the  
values to the levels measured from untreated cells. As seen in Figure 4.14a, there was a 60−70% 
reduction in CUG
exp
 levels in cells treated with 6 and 9 at 50 μM. Ligand 5 showed only a 
negligible change of CUG
exp
 levels, although a longer incubation time of 5 and 7 d led to a 
significant decrease in the level of toxic CUG
exp
 RNA (Figure 4.15a). Because of its lower 
toxicity, the dose dependence of 9 was examined by treating cells with four different 
concentrations ranging from 25 to 150 μM. As seen in Figure 14.4b, 9 clearly regulates the 
cellular CUG
exp
 mRNA levels in a dose-dependent manner. The control ligands 2 and 3 did not 
show a significant effect on the level of toxic RNA (Figure 4.14b and Figure 4.15b). 
 
 
Figure 4.15. CUG
exp
 mRNA level study. (a) CUG
exp
 mRNA levels after treatment with ligand 5. (b) Fold change 
in CUG
exp
 expression levels in DM1 model cells treated with control ligands 2 and 3. CUG
exp
 levels from 
untreated DM1 model cells as HeLa cells transfected with plasmid containing (CTG)960 was normalized to 1. 
Ligand 2 at 100 M showed no effect on the level of (CUG)exp after 72 h incubation, whereas treatment of DM1 
model cells with 3 at 50 M for 48 h resulted in an increase in CUGexp mRNA level. The error bars represent 
standard deviation of three independent triplicates. * P < 0.05, *** P < 0.001 (two tailed t-test). 
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4.7. Effects of ligand 9 on the disease phenotypes in DM1 Drosophila  
The data presented above indicate that 9 is able to engage each of three small-molecule 
intervention pathways outlined in Figure 4.1b, and it was found further to be relatively nontoxic. 
 
For these reasons, it was selected for in vivo testing in a DM1 Drosophila model,
12
 specifically 
transgenic flies that express an interrupted (CTG)480 sequence (i(CTG)480). The experiments in 
the DM1 Drosophila model were performed by our collaborators, Edwin Chan and his research 
group at the Chinese University of Hong Kong. The flies exhibit severe neurodegeneration and 
manifest a number of disease symptoms, including the well-characterized glossy and rough-eye 
phenotype that can be easily observed by microscopy (Figure 4.16). Whereas ligands 2 and 9 
 
Figure 4.16. Ligands 2 and 9 rescue eye phenotypes in DM1 Drosophila. (a) Treatment of Drosophila bearing 
i(CUG)60 with ligands 2 and 9 showed no effects on larval locomotion (left) and eyes (right), indicating that the 
ligands are relatively non-toxic. The error bars represent the standard deviation of three independent experiments 
(b) Ligands 2 and 9 reversed the disease phenotype in DM1 infected fly eyes at the concentration of 200 M. (c) 
Ligand 9 rescued DM1 phenotypes in drosophila eye in a dose-dependent manner. 
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showed no effects on eye shape of i(CTG)60 containing flies that do not have DM1 phenotypes, 
treatment of the DM1 flies with ligand 9 improved the neurodegenerative phenotype in a dose-
dependent fashion. Particularly striking is a significant reduction in glossiness and a better-
defined eye shape clearly observed after a 6-day treatment regimen (Figure 4.16). As we 
previously reported, control ligand 2 also showed reversal of the disease phenotype but less 
effectively. 
These DM1 Drosophila exhibit other phenotypes, including impaired locomotion. To test 
the ability of 2 and 9 to improve the locomotor behavior of Drosophila larvae, we used crawling 
assays.
35-37
 Untreated larvae having i(CUG)60 do not show the phenotype and crawled with an 
average speed of ca. 13 lines/min, which is considered baseline locomotion. Those expressing 
i(CUG)480 crossed only 9 lines/min (Figure 4.17b). Larvae that were treated with the highest 
doses of 2 and 9 (400 μM) showed significant improvement in locomotion with an average 
crawling speed approaching the normal baseline level of ca. 13 lines/min. Importantly, the 
phenotypic improvement with both compounds was dose-dependent, and 9, in all cases, provided 
 
 
Figure 4.17. Larvae mobility was improved after the treatment of ligands. The error bars represent standard 
deviation of three independent experiments. For each independent experiment, 10 individual larvae were studied. 
*P < 0.05, **P < 0.01, ***P < 0.001 (two-tailed t-test). 
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greater phenotypic reversal than did 2. Thus, with doses ranging from 100 to 400 μM, 9 
exhibited between 38% and 89% recovery of normal locomotor behavior, whereas 2 showed 
between 14% and 83% recovery (Figure 4.17). Because 9 regulated the level of toxic CUG
exp
 in 
cells, we performed experiments to determine whether the same activity was observed in DM1 
flies. SV40 terminator mRNA is downstream from the i(CUG)60  and i(CUG)480  regions (Figure 
4.18a). Thus, its amplification using specific primers that are detailed in the Experimental 
Section is directly correlated with CUG
exp
 mRNA levels. The SV40 mRNA was expressed 
approximately equally in larvae bearing either i(CUG)60  or i(CUG)480  (Figure 4.18b). Treatment 
with 2 and 9 at 400 μM showed no change in SV40 mRNA levels measured in larvae having  
 
i(CUG)60. In contrast and consistent with the cell studies, 9 reduced by ca. 40−60% the SV40 
mRNA levels in the i(CUG)480  larvae, whereas 2 did not. This result demonstrates the in vivo 
selectivity of 9 toward larvae expressing disease length CUG trinucleotide repeats. 
 
 
Figure 4.18. Ligand 9 regulates the level of toxic RNA in DM1 Drosophila model. (a) Diagram of i(CTG)60/480 
gene construct and the region (SV40 terminator) that was amplified to measure the level of transcribed mRNA. 
(b) Ligand 9 reduced the levels of SV40 RNA in larvae. The SV40 region of the CUG-containing RNA was 
measured relative to β-actin RNA level. The error bars represent the standard deviation of three independent 
experiments. For each independent experiment, mRNA levels from five individual larvae were determined; *P < 
0.05, **P < 0.01 (two-tailed t-test). 
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4.8. Conclusion 
The “holy grail” of DM1 therapeutic strategies would involve contraction of CTGexp to 
nondisease lengths. Such a process could represent a cure for the disease. This is a particularly 
difficult challenge because multiple processes cause the expansion and their detailed 
mechanisms are not known. For this reason, drug discovery efforts to date have largely focused 
on the toxic CUG
exp
 transcript and its gain-of-function mechanism. A number of single-target 
small molecules are now known that selectively recognize CUG
exp
 and liberate sequestered 
MBNL1. However, recent reports indicate a more complex disease pathobiology, suggesting that 
binding CUG
exp
 may not be enough to reverse all disease pathways. Thus, efforts to destroy the 
toxic RNA transcript or inhibit its formation have particular appeal. Three reported examples of 
agents that control CUG
exp
 levels include antisense agents that induced CUG
exp
 cleavage via a 
RNase H-dependent manner,
22
 a small molecule that degraded CUG
exp
  through a photo-induced 
cleavage,
24
 and (CTG·CAG)n  transcription inhibitors.
25 
The efforts described herein sought a single small-molecule agent that might intervene in 
multiple DM1 disease pathways. We discovered agents 5, 6, and 9 that, indeed, operate in three 
distinct ways. Each shows RNase-A-like activity in selectively cleaving (CUG)16 in vitro, and 
each inhibits both the in vitro transcription of CTG
exp
 and the sequestration of MBNL1 in nuclear 
foci in a DM1 model cell culture. Not all of the compounds performed equally well at each of 
these tasks. For example, 6 and 9 cleaved (CUG)16 more rapidly than did 5, and both fully 
inhibited nuclear foci formation, whereas 5 was not quite as effective. As a CTG
exp
 transcription 
inhibitor, 9 was the most effective but less selective than 6. Interestingly, the least effective 
transcription inhibitor, 6, was most effective at suppressing cellular levels of (CUG)960. Although 
this might suggest that the RNA cleaving activity is most important, the cellular suppression of 
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(CUG)960 over the 3 day period appears to well out-pace the in vitro  RNA cleavage rates. The 
latter are quite slow even at high compound concentrations. It is possible that one or more RNA 
nicks activate an endogenous RNase, or it may just reflect the complexity of the cell where 
(CUG)960 suppression will depend on many factors, including cell permeability and the 
effectiveness of the three separate targeting activities in the complex environment of the cell. 
With all of the results and particularly the low cytotoxicity exhibited by 9 taken into account, it 
was considered the most promising candidate for in vivo studies. In a DM1 Drosophila model, 9 
was found to rescue the neurodegeneration, thereby significantly reversing both the rough-eye 
phenotype and the larvae locomotor function. How does 9 function in the Drosophila? To the 
best of our knowledge, 9 is the first small molecule to control the level of CUG
exp
 in a DM1 
model organism. It is beyond the scope of this investigation to determine how 9 functions in 
vivo, but the reduction in the toxic RNA levels supports the role of its multi-target ability 
observed in earlier studies. It was especially noteworthy that the control compound 2 shows no 
suppression of the CUG
exp
 levels. 
None of the compounds described herein are able to recognize or affect the (CAG)
exp 
 
transcript, so it is able to undergo RAN translation. It is also the case that agents such as 5, 6, and 
9 that nick RNA and may act as transcription inhibitors will have to exhibit a very high level of 
selectivity to avoid undesirable off-target activity. Indeed, in the transcription assays with 9, 
some inhibition was observed with the control sequences. Although achieving such selectivity 
remains as a future challenge, the repeating nature of the trinucleotide repeat target means that a 
bi- or polyvalent strategy can easily amplify selective targeting. Most significantly, we have 
demonstrated the first rational multi-target drug discovery effort that has led to three small 
molecules that intervene in three separate pathobiological steps in DM1, with one of the agents 
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showing enhanced phenotypic reversal in two separate DM1 Drosophila assays. 
4.9. Materials and methods 
Compounds, Materials, and General Methods. The preparation and characterization of ligands 
tested in the cellular experiments are reported herein. Unless otherwise noted, 
1
H spectra were 
recorded on a 500 MHz Varian Unity Inova spectrometer. All NMR measurements were carried 
out at ambient temperature. Chemical shifts are in parts per million (ppm). Coupling constants 
(J) are reported in hertz (Hz). Electrospray ionization mass spectra (ESI-MS) were obtained by 
the Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois at 
Urbana-Champaign. All tested ligands are ≥95% pure as indicated by HPLC. 
 
Scheme 4.1. Synthesis of ligands 5 and 6 
Compounds 11, 12, 13, 15 were synthesized by following the reported procedures.
27
  
 
Compound 14. To a 35 mL round-bottomed flask containing 500 mg (2.1 mmol) of compound 
9-oxo-9,10-dihydroacridine-4-carboxylic acid (11) was added 5 mL (68.9 mmol) of SOCl2 using 
a syringe and 4 drops of anhydrous DMF. The reaction mixture was refluxed for 1 h. The 
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unreacted SOCl2 were removed azeotropically using DCM. The orange solid containing 12 was 
dried under high vacuum and used for the next reaction without further purification.  
The crude product containing 12 was dissolved in 10 mL of anhydrous DCM and cooled in 
an ice bath. The pH of the solution was adjusted to pH = 11 using anhydrous Et3N. A solution of 
809 mg (2.3 mmol) of 13 in 5 mL of anhydrous DCM was added slowly to the reaction mixture. 
The reaction was slowly warmed to room temperature and stirred overnight. The reaction was 
monitored using TLC with a mixture of ethyl acetate:hexane = 8:2. Dichloromethane was 
removed using a rotary evaporator. The obtained orange solid was dissolved in 5 mL of ethyl 
acetate and purified by a silica column chromatography using a gradient mixture of ethyl 
acetate:hexane from 2:8 to 8:2, giving compound 14 as a yellow solid (280 mg, 23%). 
1
H NMR 
(DMSO-d6): δ 11.11 (br s, NHCO, 1H), 8.76 (dd, ArH, 1H, J = 1.5, 5.5), 8.62 (dd, ArH, 1H, J = 
1.5, 7.5),  8.45 (d, ArH, 1H, J = 7.5), 8.34 (d, ArH, 1H, J = 9),   8.06-8.03 (m, ArH, 1H),  7.90-
7.85 (m, ArH, 2H),  3.60 (q, CH2, 2H, J = 5.5, 6), 3.08-3.02 (m, CH2, 4H), 2.81 (t, CH2, 2H, J = 
6.3), 2.66 (t, CH2, 4H, J = 6.3), 1.15 (br s, CH3, 18H). 
 
Compound 16. To a 50 mL round-bottomed flask containing 280 mg (0.5 mmol) of 14 in 20 mL 
of anhydrous DMF was added 109 mg (0.6 mmol) of N
2
-(4-aminobutyl)-1,3,5-triazine-2,4,6-
triamine (15) and 0.19 mL (1.1 mmol) of DIPEA. The reaction was stirred at 60 °C for 6 h. The 
solvent was removed using vacuum, giving an orange solid. The crude solid was dissolved in 5 
mL of DCM and purified by alumina column chromatography using a mixture of DCM:MeOH = 
95:5, giving compound 16 as a orange solid (240 mg, 67%). 
1
H NMR (DMSO-d6): δ 8.60 (d, 
ArH, 1H, J = 6), 8.55 (d, ArH, 1H, J = 7), 8.42 (d, ArH, 1H, J = 9), 7.97 (d, ArH, 1H, J = 8.5), 
7.75 (t, ArH, 1H, J = 7.5), 7.53 (br t, NHCO, 1H, J = 7), 7.44-7.38 (m, ArH, 2), 6.63 (br t, NH2, 
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2, J = 5.5), 6.43 (br t, NH2, 2, J = 5.8), 6.02 (br s, NH2, 2), 5.87 (br s, NH2, 2), 3.87 (br q, CH2, 
2H, J = 6.5), 3.54 (br q, CH2, 2H, J = 6), 3.15 (q, CH2, 2H, J = 6.5), 3.03 (br q, CH2, 4H, J = 
6.5), 2.76 (t, CH2, 2H, J = 6.5), 2.65 (t, CH2, 4H), 1.76 (br q, CH2, 2H, J = 7.5 ), 1.51 (br q, CH2, 
2H, J = 7), 1.21 (br s, CH3, 18H). 
 
Ligand 5. To a 50 mL round-bottomed flask containing 280 mg (0.5 mmol) of di-tert-butyl (((2-
(9-chloroacridine-4-carboxamido)-ethyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate in 20 mL of 
anhydrous DMF were added 109 mg (0.6 mmol) of N2-(4-aminobutyl)- 1,3,5-triazine-2,4,6-
triamine and 0.19 mL (1.1 mmol) of DIPEA. The reaction was stirred at 60 °C for 6 h. DMF was 
removed under high vacuum, affording an orange solid. The crude solid was dissolved in 5 mL 
of dichloromethane and purified by alumina (activated, basic) column chromatography using 
95:5 (v/v) DCM/MeOH as eluent, giving 240 mg (67%) of the desired compound as an orange 
solid. To a 100 mL round-bottomed flask containing 240 mg (0.4 mmol) of the orange solid in 
40 mL of dichloromethane was added 10 mL (131 mmol) of trifluoroacetic acid. The reaction 
was stirred at room temperature for 6 h. The solvent was removed using a rotary evaporator and 
dried under vacuum to give 410 mg (100%) of compound 5 as a yellow solid, TFA salt: 
1
H NMR 
(D2O) δ  8.40 (br d, ArH, 1H, J = 8.5), 8.22 (br d, ArH, 1H, J = 8.5), 8.12 (dd, ArH, 1H, J = 1.5, 
6), 7.81 (td, ArH, 1H, J = 1.5, 7.5), 7.66 (d, ArH, 1H, J = 7.5), 7.41 (br t, ArH, 2H, J = 8.3), 4.05 
(br t, CH2, 2H, J = 6.5), 3.55 (t, CH2, 2H, J = 7), 3.15 (br t, CH2, 2H, J = 6.3), 3.10 (br t, CH2, 
4H, J = 6.5), 2.99 (br t, CH2, 4H, J = 6.5), 2.93 (br t, CH2, 2H, J = 7), 1.85 (br q, CH2, 2H, J = 7), 
1.58 (br q, CH2, 2H, J = 7); ESI-MS (m/z) calcd for [M + H]
+
 547.3; found 547.3 [M + H]
+
. 
 
Ligand 6. To a 20 mL round-bottomed flask containing 200 mg (0.4 mmol) of compound 5 in 5 
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mL of DMF was added Et3N to pH 7. The mixture of 101 mg (0.6 mmol) of 4-imidazole acetic 
acid and 129 mg (0.6 mmol) of DCC in 5 mL of DMF was added to the above solution. The 
reaction was stirred at room temperature overnight. The solvent was removed under vacuum. 
The crude product was purified using a reversed-phase C18 column on a CombiFlash system 
(MeOH/H2O (v/v) = 0:100 to 50:50) to afford 15 mg (12%) of compound 6 as a yellow solid (15 
mg, 12%): 
1
H NMR (D2O) δ  8.56−8.50 (m, ArH, 1H), 8.48 (br s, ArH, 1H), 8.39−8.31 (m, ArH, 
1H,), 8.25 (br d, ArH, 1H, J = 8), 7.94 (br t, ArH, 1H, J = 8), 7.78 (br t, ArH, 1H, J = 8.5), 7.54 
(br t, ArH, 2H, J = 8), 7.12 (s, CH, 1H), 4.19 (br t, CH2, 2H, J = 6.8), 3.68 (br s, CH2, 2H), 3.46 
(br t, CH2, 2H, J = 6.5), 3.30−3.21 (m, CH2, 4H), 3.18−3.09 (m, CH2, 4H), 3.02−2.96 (m, CH2, 
2H), 2.96−2.91 (m, CH2, 2H), 2.03−1.96 (m, CH2, 2H), 1.74−1.69 (m, CH2, 2H); ESI-MS (m/z) 
calcd for [M + H]
+
 655.4; found 655.8 [M + H]
+
, 328.5 [M + 2H]
2+
. 
 
Scheme 4.2. Synthesis of ligand 8 
 
Compound 18. To a 50 mL round-bottom flask containing 690 mg (4.2 mmol) of compound 17
1
 
was added 10 mL of acetonitrile and 0.7 mL (5.0 mmol) of triethylamine. The suspension was 
stirred at room temperature for 5 min. To the reaction flask was added 1.7 g (4.9 mmol) of 13 at 
once, giving a clear solution. The reaction was stirred at room temperature for 2 h. Acetonitrile 
was removed using a rotary evaporator. The obtained solid was dissolved in 30 mL of MeOH. To 
the resulting solution was added 2.0 mL (19.9 mmol) of 1,4-diaminobutane at once. The reaction 
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was heated to 90 °C, and stirred for 1 h. Methanol and the excess amount of diaminobutane were 
removed by a rotary evaporator. The crude was purified by silica gel column chromatography 
with a mixture of CH2Cl2/MeOH/NH4OH = 90/9/1. Fractions containing product were combined 
and concentrated to give 1.3 g (59%) of compound 18 as a white solid.
 1
H NMR (DMSO-d6): δ 
6.75 (br s, NHBoc, 2H), 6.53–5.81 (m, ArH, 4H), 3.19–3.14 (m, CH2, 4H), 2.97 (br s, CH2, 4H), 
2.56–2.53 (t, CH2, 2H, J = 6.9), 2.46–2.44 (t, CH2, 6H, J = 6.5), 1.49–1.30 (m, CH2, 4H), 1.37 
(br s, CH3, 18H). ESI-MS (m/z) calculated for [M + H]
+
: 527.4; found 527.2. 
 
Ligand 8. To a 100 mL 24/40 round-bottom flask was added 850 mg (1.6 mmol) of melamine 18 
and 420 mg (2.0 mmol) of acridine 19. The mixture was dissolved in 20 mL of DMF. To the 
resulting yellow solution was added 0.3 mL (1.7 mmol) of DIPEA. The mixture was stirred at 60 
°C for 5 h. The solvent was removed using a rotary evaporator. The crude was purified by 
alumina (activated, basic) column chromatography using a DCM/MeOH mixture (gradient from 
100/0 to 97/3 (v/v)). The fractions containing product were combined and concentrated using a 
rotary evaporator. The yellow solid was dissolved in a mixture of 25 mL of TFA and 25 mL of 
DCM. The solution was stirred at room temperature for 5 h. The reaction was concentrated using 
a rotary evaporator, and dried overnight under high vacuum to give 876 mg (51%) of compound 
8 as a yellow solid. 
1
H-NMR (500 MHz, CD3OD-d4): δ 8.51−8.49 (m, 2H, ArH), 7.96−7.94 (m, 
2H, ArH), 7.82−7.80 (m, ArH, 2H), 7.55 (t, ArH, 2H, J = 7.9), 4.22−4.21 (m, NHCH2, 2H), 
3.49−3.45 (m, NHCH2, 4H), 3.10−3.05 (m, NH2CH2, 4H), 2.87−2.71 (m, NCH2, 6H), 2.09−2.02 
(m, CH2CH2, 2H), 1.82−1.74 (m, CH2CH2, 2H). ESI-MS (m/z) calculated for [M + H]
+
: 504.3; 
found 504.3.  
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Compound 22. To a 35 mL round-bottom flask containing 300 mg (1.3 mmol) of 20 synthesized 
using the reported protocol
5
 was added 2 mL (27.6 mmol) of SOCl2 using a syringe and 8 drops 
of dry DMF. The reaction mixture was refluxed for 1 h. The unreacted SOCl2 was removed 
azeotropically using DCM. The crude orange product containing 21 was dried under high 
vacuum and used for the next reaction without further purification. 
 
Scheme 4.3. Synthesis of ligand 4  
 
The crude product containing 21 was dissolved in 10 mL of anhydrous DCM and cooled in an 
ice bath. The pH of the solution was adjusted to pH = 11 using anhydrous Et3N. A solution of 
400 mg (1.2 mmol) of 13 in 5 mL of anhydrous DCM was added slowly to the reaction mixture. 
The reaction was slowly warmed up to room temperature and stirred overnight. The reaction was 
monitored using TLC with a mixture of ethyl acetate:hexane = 8:2. Dichloromethane was 
removed using a rotary evaporator. The resultant orange solid was dissolved in 5 mL of ethyl 
acetate and purified by silica column chromatography using a gradient mixture of ethyl 
acetate:hexane from 2:8 to 8:2, giving compound 22 as a yellow solid (300 mg, 25%). 
1
H NMR 
(DMSO-d6): δ  8.90 (t, ArH, 1H, J = 3.3), 8.47 – 8.42 (m, ArH, 1H), 8.29 – 8.24 (m, ArH, 2H), 
7.99 (ddd, ArH, 1H, J = 8.4, 6.6, 1.4,), 7.82 (ddd, ArH, 1H, J = 8.9, 6.6, 1.2), 6.69 (t, ArH, 1H, J 
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= 5.7), 3.38 (q, CH2, 2H, J = 6.5), 2.99 (q, CH2, 4H, J = 6.5), 2.66 (t, CH2, 2H, J = 6.8), 2.52 (t, 
CH2, 4H, J = 6.8), 1.32 (br s, CH3, 18H). 
 
Ligand 4. To a 50 mL round bottom flask containing 270 mg (0.5 mmol) of compound 22 in 20 
mL of anhydrous DMF was added 105 mg (0.5 mmoL) of N
2
-(4-aminobutyl)-1,3,5-triazine-
2,4,6-triamine (15) and 0.184 mL (1.1 mmol) of DIPEA. The reaction was stirred at 60 °C for 6 
h. DMF was removed using vacuum, affording an orange solid. The crude solid was dissolved in 
5 mL of DCM and purified by alumina column chromatography with a mixture of DCM:MeOH 
= 95:5, giving compound 23  as a orange solid (260 mg, 72%). To a 100 mL round bottom flask 
containing 260 mg of compound 23 in 20 mL of DCM was added 10 mL of TFA. The reaction 
was stirred at room temperature for 6 h. The solvent was removed using a rotary evaporator and 
dried under vacuum to give compound 4 as a yellow TFA salt (100%). 
1
H NMR (D2O): 8.70 (t, 
ArH, 1H, J = 2.6), 8.22 (s, ArH, 1H), 8.04 (qd, ArH, 1H, J = 8.9, 1.7), 7.83–7.77 (m, ArH, 1H), 
7.60 (t, 2H, ArH, J = 6.9), 7.40 (s, ArH, 1H), 4.13–4.07 (m, CH2, 2H), 3.54 (t, CH2, 2H, J = 6.9), 
3.17 (q, CH2, 2H, J = 1.7), 3.11 (br d, CH2, 4H, J = 6.4), 3.04 (br s, CH2, 4H), 2.96 (br s, CH2, 
2H), 1.88 (br s, CH2, 2H), 1.60 (br s, CH2, 2H).  
 
Scheme 4.4. Synthesis of ligand 9 
 
Ligand 9. To a 100 mL oven-dried round-bottomed flask was added 250 mg (0.9 mmol) of 
diethyl terephthalimidate hydrochloride. The white solid was dissolved in 15 mL of anhydrous 
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ethanol. To the resulting suspension was added 0.3 mL (2.2 mmol) of anhydrous Et3N followed 
by 1.0 g (1.9 mmol) of di-tert-butyl (((2-((4-amino-6-((4-aminobutyl)amino)-1,3,5-triazin-2-
yl)amino)ethyl)azanediyl)bis-(ethane-2,1-diyl))dicarbamate at once. The resulting suspension 
was stirred at room temperature for 1 d. The solvent was removed using a rotary evaporator. The 
crude was dissolved in 20 mL of 2 N ethanolic HCl. The reaction was stirred at room 
temperature overnight. Ethanol was removed using a rotary evaporator. The crude was purified 
by a Sephadex CM-25 column chromatography using an aqueous solution of NH4HCO3 from 0.1 
to 1.0 M. Fractions containing products were combined and concentrated at 60 °C using a rotary 
evaporator. The solid was dissolved in 80 mL of 0.1 M aqueous HCl. The resulting solution was 
concentrated using a rotary evaporator to give 390 mg (40%) of compound 9 as a white HCl salt: 
1
H NMR (DMSO-d6) δ 10.27 (br s, NH, 2H), 9.80 (br s, NH, 2H), 9.46−9.41 (m, NH, 2H), 
8.42−7.90 (m, ArH, 8H), 8.00 (s, ArH, 4H), 3.87 (br s, NH2, 8H), 3.54−3.35 (m, CH2, 12H), 2.96 
(br s, CH2, 8H), 2.76−2.62 (m, CH2, 12H), 1.71−1.64 (m, CH2, 8H); ESI-MS (m/z) calcd for [M 
+ H]
+
: 781.6; found 781.6. 
 
RNA was purchased from Integrated DNA Technologies (Coralville, IA) and GE Dharmacon 
(Lafayette, CO). RNA samples were dissolved in THE Ambion RNA storage solution and stored 
at −20 °C. UV absorbance of the RNA solutions was measured at 25 °C on a Shimadzu UV-
2501PC spectrophotometer. The concentration of the double-stranded RNA was calculated using 
Beer’s law with the extinction coefficient at 260 nm provided by the supplier. The GFP-DT0 and 
GFP-DT960 plasmids were the gifts from Auinash Kalsotra (University of Illinois, Urbana-
Champaign, IL); the DT960 minigene plasmid from Thomas Cooper (Baylor College of 
Medicine, Houston, Texas); the (CTG)74 plasmid from Maurice Swanson (University of Florida, 
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Gainesville, FL, and the IR  minigene plasmid  from Nicholas Webster (University of California, 
San Diego). 
 
RNA Cleavage Experiments. RNA was fast-folded at 95 °C for 5 min and then placed in ice for 
10 min. RNA with a final concentration of 100 nM was incubated with 100 μM cleaving agents 
(in screening assays) or with ligand 9 at different concentrations (5, 10, 50, 100 μM). The 
cleaving buffer was 50 mM Tris buffer (pH 7.4) containing 150 mM NaCl and 2 mM MgCl2. 
The final volume of the reaction mixture was 10 μL. The reaction was quenched by adding 8 μL 
of 8M urea and 2 μL of RNA loading dye or 1 μL of HIV FS RNA as a spike and 1 μL RNA 
loading dye (in screening experiments) followed by heating at 95 °C for 5 min. The reaction 
mixture was separated on a 20% RNA denaturing gel. For nonlabeled RNA, the gel was stained 
with EtBr and observed under UV. For TAMRA−(CUG)16, the gel was scanned using a Typhoon 
instrument in the Biotech Center Lab (Noyes Laboratory, School of Chemical Sciences, 
University of Illinois, Urbana, IL). The images were worked up using ImageJ software (NIH). 
Foci dispersion and IR splicing experiments followed the reported protocols.
12
  
 
Cellular mRNA Level Study with Dox Treatment. Approximately, 50 000 HeLa cells were 
plated on a 12-well plate in DMEM media supplemented with high glucose, L-glutamine, and no 
antibiotics a day before transfection. HeLa cells were transfected with 1 μg of GFP-DT0 or GFP-
DT960 plasmids using Lipofectamine (Life Technologies) following the recommended protocol. 
After 4 h, the transfection cocktail was replaced with the growing media, and cells were treated 
with 1 μg of Dox. Ligands were treated at the same time at desired concentrations for 3 days. 
Cells were checked by fluorescence microscopy for a GFP signal as a marker of successful 
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transfection and then harvested. Total mRNA was isolated using E.Z.N.A. total RNA kit I 
(Omega). Approximately, 1.5 μg of total mRNA was subjected to DNase treatment to remove all 
DNA contaminant. cDNA synthesized using Iscript cDNA synthesis kit (Bio-Rad) was used as 
the template for real-time PCR using SYBR master mix (Applied Biosystem). The results from 
real-time PCR experiments were analyzed using the ΔΔCt method.38 The mRNA levels of exon 
15 upstream of CUGexp were measured relative to PABP mRNA levels. The difference in the 
expression level of exon 15 RNA transcript between treated GFP-DT0 and GFP-DT960 samples 
was compared with the one of untreated samples that were normalized to 100%. The primers 
were used in the experiments: E15upF: 5′-TCG GAG CGG TTG TGA ACT-3′; E15upR: 5′-GTT 
CGC CGT TGT TCT GTC-3′; PabpF: 5′-CTG CTG TTC ATG TGC AAG GT-3′; PabpR: 5′-
CAA CAG CAT GCC AGT GAT T-3′. 
 
In Vitro Transcription of (CTG·CAG)74. A 10 μL mixture contained 15 ng of linearized 
plasmid (CTG)74 or control plasmid templates, 0.5 mM each rATP, rCTP, rGTP, and rUTP, and 
0.5 U T7 polymerase (Biolab) in 1X T7 transcription buffer (80 mM Tris pH 8.3, 10 mM MgCl2, 
2 mM spermine, 0.1% Triton-X, 10 mM NaCl) was incubated at 37 °C for 2 h. Ligand was 
added with the final concentrations of 0, 1, 10, 50, and 100 μM prior to incubation. Reactions 
were quenched by adding 8 μL of 8 M urea and 2 μL of denaturing dye (95% formamide, 5 mM 
EDTA, 0.025% each xylene cyanol and bromophenol blue) and heating to 95 °C for 5 min. Of 
this solution, 15 μL was run on a 8% denaturing polyacrylamide gel in 0.5X TBE. The gel was 
stained with EtBr. Bands were quantified using the ImageJ (NIH). The intensity of (CUG)74 band 
(ca. 260 nt) was normalized to that from the untreated transcription reaction. The control 
plasmids were pTRI-Xef plasmid provided with MEGAscript T7 transcription kit (Life 
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Technologies) that expresses 1.89 kb RNA transcript and another non-repeat-containing plasmid 
expressing a 197 nt RNA transcript. 
 
Drug Treatment in DM1 Drosophila. Drosophila lines were cultured in standard cornmeal 
medium supplemented with dry yeasts. Fly lines bearing UAS-(CTG)60 and UAS-(CTG)480
39,40 
were kind gifts of Prof. Rub n Artero Allepuz (Universitat de Vale ncia, Estudi General, Spain). 
The gmr-GAL4
41
 and 24B-GAL4
42
 lines were used to drive UAS transgene expression in eye 
and muscles, respectively. Ligands 2 and 9 were dissolved in ddH2O and mixed with fly food. 
Genetic crosses were set up in drug-containing fly food at 21.5 °C for external eye assay and at 
25 °C for larval crawling assay and real-time PCR analysis. For additional details, see REF. 12. 
 
Larval Crawling Assay. Larval crawling assays were performed as described in Lanson et al.
35
 
Ten wandering third instar larvae were washed in ddH2O and placed on a 2% agarose gel in a 15 
cm Petri dish with gridlines spaced at 0.5 cm. The larvae were allowed to acclimate for a period 
of 1 min, and the total number of gridlines that the posterior end of the larvae passed in 1 min 
was determined. Each set of experiments was repeated independently three times using larvae 
collected from separate genetic crosses. 
 
RNA Extraction and Real-Time PCR. RNA was extracted from third instar larvae by TRIzol 
reagent (Invitrogen). One microgram of purified RNA was used for reverse transcription via the 
ImPromII reverse transcription system (Promega). Real-time PCR gene expression assays were 
performed on an ABI 7500 real-time PCR system, using the SYBR Green PCR master mix 
(ABI) with the following primers: SV40_F: 5′-GGA AAG TCC TTG GGG TCT TC-3′; 
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SV40_R: 5′-GGA ACT GAT GAA TGG GAG CA-3′; actin_F: 5′-ATG TGC AAG GCC GGT 
TTC GC-3′ and actin_R: 5′-CGA CAC GCA GCT CAT TGT AG-3′. Each reaction was 
performed in duplicate. Quantification of gene expression was calculated according to the 2
−ΔΔCt
 
method, where ΔΔCt = (Ct,target − Ct,actin)experimental − (Ct,target − Ct,actin)negative 
control. Each set of experiments was repeated independently three times using larvae collected 
from separate genetic crosses. 
 
Isothermal Titration Calorimetry. ITC measurements were performed at 25 °C on a MicroCal 
VP-ITC (MicroCal, Inc., Northampton, MA). A standard experiment consisted of titrating 10 μL 
of a 500 μM ligand solution from a 250 μL syringe (rotating at 300 rpm) into a sample cell 
containing 1.42 mL of a 10 μM DNA or RNA solution. An ITC experiment consisted of 28 total 
injections (first injection was 5 μL, subsequent injections were 10 μL), with a 10 s duration per 
injection and delay of 380 s between injections. The initial delay prior to the first injection was 
300 s. To derive the heat associated with each injection, the area under each isotherm 
(microcalories per second versus seconds) was determined by integration by the graphing 
program Origin 7.0 (MicroCal, Inc. Northampton, MA). The first data point from each ITC 
experiment was omitted when fitting to binding models because of the possible diffusive mixing 
of material near the tip of the syringe. The fitting requirements were such that the 
thermodynamic parameters were derived from curves that produced the lowest amount of 
deviation. In most cases, fitting to a sequential site-binding/model-binding site gave the most 
accurate data. The ligand stock solution was 10 mM in water. Double-stranded and hairpin DNA 
or RNA solutions were freshly prepared by mixing required volumes of the corresponding 
single-stranded oligomers and annealing by heating in a water bath at >90 °C for 5 min and 
 106 
slowly cooling to room temperature. MOPS buffer solution (1 M), NaCl solution (5 M), and 
biological grade water were added to make up an oligonucleotide solution with 20 mM MOPS 
(pH 7.0 ± 0.2), 300 mM NaCl. 
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